

Memantine is a clinically well tolerated N-methyl-d-aspartate receptor antagonist—a review of preclinical data

Neuropharmacology

38, 735-767

DOI: 10.1016/s0028-3908(99)00019-2

Citation Report

#	ARTICLE	IF	CITATIONS
1	NMDA antagonists: unequal to the task or unequal to each other - or both?. European Journal of Pain, 1999, 3, 185-187.	1.4	4
2	Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists. Neurotoxicity Research, 1999, 1, 299-310.	1.3	17
3	Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg ²⁺ In hippocampal slices. Neuropharmacology, 1999, 38, 1253-1259.	2.0	102
4	Drug treatment in dementia. Current Opinion in Psychiatry, 2000, 13, 415-421.	3.1	3
5	Subcortical Vascular Dementia as a Specific Target for Clinical Trials. Annals of the New York Academy of Sciences, 2000, 903, 510-521.	1.8	36
6	Novel approaches in diagnosis and therapy of Creutzfeldtâ€“Jakob disease. Mechanisms of Ageing and Development, 2000, 116, 193-218.	2.2	41
7	Role of high-energy phosphates and their metabolites in protection of carbofuran-induced biochemical changes in diaphragm muscle by memantine. Archives of Toxicology, 2000, 74, 13-20.	1.9	32
8	Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 425-432.	1.4	46
9	Are NMDA receptors involved in opiate-induced neural and behavioral plasticity?. Psychopharmacology, 2000, 151, 121-141.	1.5	128
10	Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Psychopharmacology, 2000, 151, 175-183.	1.5	51
11	Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bulletin of Experimental Biology and Medicine, 2000, 130, 629-632.	0.3	18
12	Neuroprotective and symptomatological action of memantine relevant for alzheimerâ€™s disease â€” a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research, 2000, 2, 85-97.	1.3	211
13	Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - toward an understanding of their favorable tolerability. Amino Acids, 2000, 19, 133-149.	1.2	103
14	Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids, 2000, 19, 151-155.	1.2	25
15	Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists - in vitro characterisation. Amino Acids, 2000, 19, 157-166.	1.2	34
16	NMDA channel blockers: memantine and amino-alkylcyclohexanes - In vivo characterization. Amino Acids, 2000, 19, 167-172.	1.2	35
17	Evaluation of memantine for neuroprotection in dementia. Expert Opinion on Investigational Drugs, 2000, 9, 1397-1406.	1.9	100
18	Intracellular Mechanisms of Antidepressant Drug Action. Harvard Review of Psychiatry, 2000, 8, 161-174.	0.9	23

#	ARTICLE	IF	CITATIONS
19	Preclinical psychopharmacology of AIDS-associated dementia: lessons to be learned from the cognitive psychopharmacology of other dementias. <i>Journal of Psychopharmacology</i> , 2000, 14, 197-204.	2.0	9
20	A Prospective PMS Study to Validate the Sensitivity for Change of the D-Scale in Advanced Stages of Dementia Using the NMDA-Antagonist Memantine. <i>Pharmacopsychiatry</i> , 2000, 33, 103-108.	1.7	30
21	Successful Trial of Amantadine Hydrochloride for Two Patients with Alternating Hemiplegia of Childhood. <i>Neuropediatrics</i> , 2000, 31, 307-309.	0.3	15
22	Synaptic Plasticity and Memory: An Evaluation of the Hypothesis. <i>Annual Review of Neuroscience</i> , 2000, 23, 649-711.	5.0	2,363
23	Quantitative Analysis of Tetrapentylammonium-Induced Blockade of Open N-Methyl-D-Aspartate Channels. <i>Biophysical Journal</i> , 2000, 79, 1324-1335.	0.2	11
24	The N-methyl-d-aspartate antagonistic and opioid components of d-methadone antinociception in the rat spinal cord. <i>Neuroscience Letters</i> , 2000, 296, 117-120.	1.0	32
25	Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures. <i>Neuropharmacology</i> , 2000, 39, 2244-2254.	2.0	36
26	Differential effects of NMDA receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. <i>Neuropharmacology</i> , 2000, 39, 631-642.	2.0	31
27	No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. <i>Life Sciences</i> , 2000, 66, 1079-1083.	2.0	77
28	Agents in Development for Anxiety Disorders. <i>CNS Drugs</i> , 2000, 13, 421-431.	2.7	16
29	Apoptosis modulators in the therapy of neurodegenerative diseases. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 747-764.	1.9	83
30	The Neuroprotective Agent Memantine Induces Brain-Derived Neurotrophic Factor and trkB Receptor Expression in Rat Brain. <i>Molecular and Cellular Neurosciences</i> , 2001, 18, 247-258.	1.0	130
31	Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. <i>Pain</i> , 2001, 91, 101-109.	2.0	110
32	Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. <i>Pain</i> , 2001, 91, 201-207.	2.0	19
33	Pharmacology and behavioral pharmacology of the mesocortical dopamine system. <i>Progress in Neurobiology</i> , 2001, 63, 241-320.	2.8	406
34	Zinc in the retina. <i>Progress in Neurobiology</i> , 2001, 64, 219-249.	2.8	141
35	Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. <i>Neuroscience Letters</i> , 2001, 309, 45-48.	1.0	28
36	Increased expression of neuronal Src and tyrosine phosphorylation of NMDA receptors in rat brain after systemic treatment with MK-801. <i>Neuropharmacology</i> , 2001, 40, 469-481.	2.0	8

#	ARTICLE	IF	CITATIONS
37	The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. <i>Neuropharmacology</i> , 2001, 40, 749-760.	2.0	145
38	Memantine Inhibits Efferent Cholinergic Transmission in the Cochlea by Blocking Nicotinic Acetylcholine Receptors of Outer Hair Cells. <i>Molecular Pharmacology</i> , 2001, 60, 183-189.	1.0	39
39	Combination Therapies and the Theoretical Limits of Evidence-Based Medicine. <i>Neuroepidemiology</i> , 2001, 20, 57-64.	1.1	29
40	â€œLow-Techâ€•Neuroprotection for Brain Injury. <i>Journal of Head Trauma Rehabilitation</i> , 2001, 16, 206-209.	1.0	1
41	The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. <i>Psychopharmacology</i> , 2001, 157, 1-10.	1.5	119
42	Separation methods for tricyclic antiviral drugs. <i>Biomedical Applications</i> , 2001, 764, 313-325.	1.7	14
43	Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. <i>British Journal of Pharmacology</i> , 2001, 132, 693-702.	2.7	40
44	Glutamate release promotes growth of malignant gliomas. <i>Nature Medicine</i> , 2001, 7, 1010-1015.	15.2	502
45	Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. <i>Brain Research</i> , 2001, 911, 96-100.	1.1	110
46	Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw in rats. <i>European Journal of Pharmacology</i> , 2001, 423, 17-26.	1.7	43
47	NMDA receptors as targets for drug action in neuropathic pain. <i>European Journal of Pharmacology</i> , 2001, 429, 71-78.	1.7	210
48	The N-methyl-D -aspartate antagonist memantine has no neuroprotective effect during hypothermic circulatory arrest: A study in the chronic porcine model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 121, 957-970.	0.4	33
49	Distribution of an NMDA receptor:GFP fusion protein in sensory neurons is altered by a C-terminal construct. <i>Journal of Neurochemistry</i> , 2001, 77, 23-33.	2.1	17
50	Antidepressant therapy: new targets for drug development. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 1693-1711.	2.4	5
51	The NMDA Receptor Complex: A Promising Target for Novel Antiepileptic Strategies. <i>Current Medicinal Chemistry</i> , 2001, 8, 1275-1289.	1.2	82
52	Physiology and pathophysiology of basal ganglia: Impact on motor system function. <i>European Journal of Sport Science</i> , 2001, 1, 1-46.	1.4	0
53	Drug treatment of Alzheimerâ€™s disease. <i>Reviews in Clinical Gerontology</i> , 2002, 12, 165-173.	0.5	0
54	A Novel N-Methyl-d-aspartate Receptor Open Channel Blocker with in Vivo Neuroprotectant Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 163-173.	1.3	41

#	ARTICLE	IF	CITATIONS
55	NMDA sensitization and stimulation by peroxynitrite, nitric oxide, and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. <i>FASEB Journal</i> , 2002, 16, 1407-1417.	0.2	67
56	Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia. <i>Stroke</i> , 2002, 33, 1834-1839.	1.0	507
57	Modulation of Blood-Brain Barrier Dysfunction and Neurological Deficits during Acute Experimental Allergic Encephalomyelitis by the N-Methyl-D-aspartate Receptor Antagonist Memantine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 50-57.	1.3	73
58	Neuroprotective Effect of Memantine in Different Retinal Injury Models in Rats. <i>Journal of Glaucoma</i> , 2002, 11, 474-480.	0.8	164
59	Non-Cholinergic Strategies for Treating and Preventing Alzheimer's Disease. <i>CNS Drugs</i> , 2002, 16, 811-824.	2.7	123
60	Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. <i>Neuropharmacology</i> , 2002, 42, 1024-1030.	2.0	164
61	Modeling of the Pore Domain of the GLUR1 Channel: Homology with K ⁺ Channel and Binding of Channel Blockers. <i>Biophysical Journal</i> , 2002, 82, 1884-1893.	0.2	49
62	Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 127-138.	2.5	85
64	Disturbances in the Amino Acid Transmitter Systems in Cognitive Disorders Classified and Diagnosed According to DSM-IV. , 0, , 247-260.		0
65	Modulation of formalin-induced behaviors and edema by local and systemic administration of dextromethorphan, memantine and ketamine. <i>European Journal of Pharmacology</i> , 2002, 450, 153-162.	1.7	52
66	Neuroprotection by memantine against neurodegeneration induced by Î²-amyloid(1-40). <i>Brain Research</i> , 2002, 958, 210-221.	1.1	263
67	Memantine offers new possibilities for the treatment of VaD. <i>Lancet Neurology</i> , The, 2002, 1, 469.	4.9	0
68	Retinal ganglion cell disorders: types and treatments. <i>Progress in Retinal and Eye Research</i> , 2002, 21, 465-484.	7.3	53
69	Neuropharmacologic targets and agents in fibromyalgia. <i>Current Pain and Headache Reports</i> , 2002, 6, 267-273.	1.3	2
70	The effects of NMDA receptor antagonists on acute morphine antinociception in mice. <i>Amino Acids</i> , 2002, 23, 163-168.	1.2	24
71	Novel approaches to targeting glutamate receptors for the treatment of chronic pain: Review article. <i>Amino Acids</i> , 2002, 23, 169-176.	1.2	43
72	NMDA antagonists exacerbate neuronal death caused by proteasome inhibition in cultured cortical and striatal neurons. <i>European Journal of Neuroscience</i> , 2002, 15, 419-428.	1.2	33
73	Continuous Brachial Plexus Analgesia and NMDA-receptor Blockade in Early Phantom Limb Pain: A Report of Two Cases. <i>Pain Medicine</i> , 2002, 3, 156-160.	0.9	29

#	ARTICLE	IF	CITATIONS
74	Chronic multichannel recordings from organotypic hippocampal slice cultures: protection from excitotoxic effects of NMDA by non-competitive NMDA antagonists. <i>Journal of Neuroscience Methods</i> , 2002, 120, 193-202.	1.3	49
75	Blocker studies of the functional architecture of the NMDA receptor channel. <i>Neuroscience and Behavioral Physiology</i> , 2002, 32, 157-171.	0.2	30
76	Neuroprotective potential of ionotropic glutamate receptor antagonists. <i>Neurotoxicity Research</i> , 2002, 4, 119-126.	1.3	42
77	The neurobiology of opiate tolerance, dependence and sensitization: Mechanisms of NMDA receptor-dependent synaptic plasticity. <i>Neurotoxicity Research</i> , 2002, 4, 373-391.	1.3	78
78	Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons. <i>Bulletin of Experimental Biology and Medicine</i> , 2003, 136, 474-477.	0.3	91
79	The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. <i>Neuroscience and Behavioral Physiology</i> , 2003, 33, 273-278.	0.2	8
80	The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: Therapeutic potential. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 373-378.	2.0	10
81	Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. <i>Psychopharmacology</i> , 2003, 165, 245-251.	1.5	54
82	Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats. <i>Psychopharmacology</i> , 2003, 165, 378-385.	1.5	26
83	Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats. <i>Brain Research</i> , 2003, 994, 188-192.	1.1	9
84	The clinically available NMDA receptor antagonist dextromethorphan attenuates acute morphine withdrawal in the neonatal rat. <i>Developmental Brain Research</i> , 2003, 142, 209-213.	2.1	12
85	Glutamate and the glutamate receptor system: a target for drug action. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, S33-S40.	1.3	103
86	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, S23-S32.	1.3	327
87	NMDA-mediated mechanisms in cortical excitability changes after limb amputation. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 179-184.	1.0	43
88	Vascular Dementia: Distinguishing Characteristics, Treatment, and Prevention. <i>Journal of the American Geriatrics Society</i> , 2003, 51, S296-S304.	1.3	188
89	Inhibition of human $\alpha 7$ nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. <i>British Journal of Pharmacology</i> , 2003, 140, 1313-1319.	2.7	71
90	Evaluation of memantine for the treatment of Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2305-2313.	0.9	52
91	Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. <i>Brain Research Bulletin</i> , 2003, 59, 485-493.	1.4	35

#	ARTICLE	IF	CITATIONS
92	Possible Role for Memantine in Protecting Retinal Ganglion Cells from Glaucomatous Damage. Survey of Ophthalmology, 2003, 48, S38-S46.	1.7	90
93	Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neuroscience Letters, 2003, 343, 205-209.	1.0	42
94	Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain – results of a randomized double-blinded, placebo-controlled trial. Pain, 2003, 103, 277-283.	2.0	122
95	Reduced activity of hippocampal group-I metabotropic glutamate receptors in learning-prone rats. Neuroscience, 2003, 122, 277-284.	1.1	11
96	The Yin and Yang of NMDA receptor signalling. Trends in Neurosciences, 2003, 26, 81-89.	4.2	583
97	Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. Behavioural Brain Research, 2003, 144, 25-35.	1.2	36
98	The Glutamatergic System and Alzheimer's Disease. CNS Drugs, 2003, 17, 641-652.	2.7	220
99	Non-cholinergic strategies have a potential role in the management of Alzheimer's disease. Drugs and Therapy Perspectives, 2003, 19, 7-10.	0.3	0
100	Pharmacoeconomic aspects of memantine (Ebixa®) in the treatment of Alzheimer's disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 675-680.	0.7	4
101	Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?. Expert Opinion on Pharmacotherapy, 2003, 4, 1857-1860.	0.9	164
102	Antinociceptive Activity of the N-Methyl-d-aspartate Receptor Antagonist N-(2-Indanyl)-glycinamide Hydrochloride (CHF3381) in Experimental Models of Inflammatory and Neuropathic Pain. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 804-814.	1.3	77
103	The induction of N -methyl-D-aspartate receptor-dependent long-term potentiation. Philosophical Transactions of the Royal Society B: Biological Sciences, 2003, 358, 635-641.	1.8	37
104	Diffusion-controlled reactions with a binding site hidden in a channel. Journal of Chemical Physics, 2003, 118, 2367-2373.	1.2	14
105	Pharmacological Modulation of Perceptual Learning and Associated Cortical Reorganization. Science, 2003, 301, 91-94.	6.0	265
106	Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease. Pharmacoeconomics, 2003, 21, 327-340.	1.7	145
107	Chapter 21 Disease-Modifying Therapies in Motor Neuron Disorders: The Present Position and Potential Future Developments. Blue Books of Practical Neurology, 2003, 28, 497-544.	0.1	1
108	Treatment of dementia with neurotransmission modulation. Expert Opinion on Investigational Drugs, 2003, 12, 1633-1654.	1.9	31
109	Current Treatment for Alzheimer Disease and Future Prospects. Alzheimer Disease and Associated Disorders, 2003, 17, S105-S113.	0.6	249

#	ARTICLE	IF	CITATIONS
110	Therapeutic Strategies for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, S114-S122.	0.6	24
111	Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice. <i>Behavioural Pharmacology</i> , 2003, 14, 237-244.	0.8	57
112	Tender Points as Predictors of Distress and the Pharmacologic Management of Fibromyalgia Syndrome. <i>American Journal of Therapeutics</i> , 2003, 10, 176-192.	0.5	22
113	Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. <i>International Clinical Psychopharmacology</i> , 2003, 18, 81-85.	0.9	60
114	Memantine (Ebixa®) in the later stages of dementia. <i>British Journal of Hospital Medicine</i> , 2003, 64, 654-657.	0.3	4
115	Chapter 1. Current and emerging opportunities for the treatment of neuropathic pain. <i>Annual Reports in Medicinal Chemistry</i> , 2003, 38, 1-10.	0.5	2
116	Repeated spatial acquisition: Effects of NMDA antagonists and morphine.. <i>Experimental and Clinical Psychopharmacology</i> , 2003, 11, 79-90.	1.3	8
117	The emerging role of glutamate as a new pharmacologic target.. <i>Professional Psychology: Research and Practice</i> , 2003, 34, 444-448.	0.6	2
118	Treatments for stroke. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 103-122.	1.0	23
120	Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects. <i>Journal of Neuroscience</i> , 2003, 23, 349-357.	1.7	720
121	Memantine. <i>Hospital Pharmacy</i> , 2004, 39, 254-263.	0.4	0
123	Efficacy and Safety of Memantine Treatment for Reduction of Changes Associated with Experimental Glaucoma in Monkey, II: Structural Measures. , 2004, 45, 2640.		168
124	Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2004, 5, 84-98.	1.4	50
125	Memantine, an NMDA Antagonist, Prevents the Development of Hyperthermia in an Animal Model for Serotonin Syndrome. <i>Pharmacopsychiatry</i> , 2004, 37, 57-62.	1.7	38
126	Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 317.	3.8	1,186
127	Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice. <i>Journal of Neuroscience</i> , 2004, 24, 828-835.	1.7	113
128	Identification of Genes Regulated by Memantine and MK-801 in Adult Rat Brain by cDNA Microarray Analysis. <i>Neuropsychopharmacology</i> , 2004, 29, 1070-1079.	2.8	36
129	Memantine hydrochloride. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 109-110.	21.5	75

#	ARTICLE	IF	CITATIONS
130	Neurological disorders. Nature Reviews Drug Discovery, 2004, 3, S38-S40.	21.5	1
131	Effects of NMDA receptor antagonists on olfactory learning and memory in the honeybee (<i>Apis</i>) Tj ETQq1 1 0.784314 rgBT /Overlock 10 1.3 76		
132	Coupling between Neuronal and Glial Cells via Glutamate Metabolism in Brain of Healthy Persons and Patients with Mental Disorders. Biochemistry (Moscow), 2004, 69, 705-719.	0.7	11
133	Neurotrophins as Mediators of Drug Effects on Mood, Addiction, and Neuroprotection. Molecular Neurobiology, 2004, 29, 289-302.	1.9	84
134	Comparison of the Anticonvulsive Activities of Organic Mono- and Dications with Their Abilities to Inhibit NMDA and AMPA Glutamate Receptors. Neuroscience and Behavioral Physiology, 2004, 34, 181-187.	0.2	3
135	No nerve growth factor response to treatment with memantine in adult rats. Journal of Neural Transmission, 2004, 111, 181-190.	1.4	12
136	Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology, 2004, 172, 16-24.	1.5	75
137	Synthesis and biological evaluation of pentacyclo[5.4.0.02,6.03,10.05,9]undecane derivatives as potential therapeutic agents in Parkinson's disease. Bioorganic and Medicinal Chemistry, 2004, 12, 1799-1806.	1.4	63
138	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-175.	2.0	0
139	Glutamate and anxiety. European Neuropsychopharmacology, 2004, 14, 175-183.	0.3	183
140	Neuroprotection in Glaucoma. Essentials in Ophthalmology, 2004, , 29-38.	0.0	0
141	Emerging targets for the pharmacology of learning and memory. Pharmacological Research, 2004, 50, 111-122.	3.1	26
142	Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx, 2004, 1, 101-110.	6.0	335
143	Alzheimer's Disease. New England Journal of Medicine, 2004, 351, 56-67.	13.9	1,221
144	Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1035-1043.	2.5	56
145	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-183.	2.0	35
146	Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology, 2004, 47, 408-413.	2.0	36
147	Effects of distinct classes of N-methyl-d-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss in vitro: suppression by NR2B-selective antagonists. Neuropharmacology, 2004, 47, 1008-1020.	2.0	31

#	ARTICLE	IF	CITATIONS
148	Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. <i>Neurochemistry International</i> , 2004, 45, 583-595.	1.9	782
149	Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. <i>Neuroscience Letters</i> , 2004, 365, 132-136.	1.0	54
150	Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1389-1394.	0.9	73
152	NR2B containing NMDA receptor dependent windup of single spinal neurons. <i>Neuropharmacology</i> , 2004, 46, 23-30.	2.0	25
153	Intraarticular Pretreatment with Ketamine and Memantine Could Prevent Arthritic Pain: Relevance to the Decrease of Spinal c-Fos Expression in Rats. <i>Anesthesia and Analgesia</i> , 2004, 99, 152-158.	1.1	31
155	What Is the Rationale for New Treatment Strategies in Alzheimer's Disease?. <i>CNS Spectrums</i> , 2004, 9, 6-12, 31.	0.7	15
156	Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. <i>Journal of Alzheimer's Disease</i> , 2005, 6, S61-S74.	1.2	151
157	A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice. <i>Behavioural Pharmacology</i> , 2005, 16, 155-161.	0.8	49
158	Alzheimer's Disease: Current and Future Treatments. , 2005, , 329-354.		1
159	Excitotoxicity. , 2005, , 291-313.		1
160	Memantine for dementia. , 2005, , CD003154.		31
162	Interaction between neurotransmitter antagonists and effects of sacral neuromodulation in rats with chronically hyperactive bladder. <i>BJU International</i> , 2005, 96, 900-908.	1.3	19
163	Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding. <i>Brain Research</i> , 2005, 1041, 132-142.	1.1	28
164	Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. <i>Brain Research</i> , 2005, 1052, 156-162.	1.1	43
165	Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. <i>Journal of Pharmacological and Toxicological Methods</i> , 2005, 52, 264-273.	0.3	37
166	Magnesium as NMDA receptor blocker in the traditional Chinese medicine Danshen. <i>Phytomedicine</i> , 2005, 12, 173-177.	2.3	7
167	The NMDA antagonist memantine affects training induced motor cortex plasticity—a study using transcranial magnetic stimulation. <i>BMC Neuroscience</i> , 2005, 6, 35.	0.8	29
168	Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor K- β in an animal model of repeated trauma. <i>Human Psychopharmacology</i> , 2005, 20, 367-373.	0.7	41

#	ARTICLE	IF	CITATIONS
169	Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies. <i>Drug Development Research</i> , 2005, 64, 71-81.	1.4	16
170	Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 395-402.	2.2	141
171	Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: A focus on pentacycloundecane derivatives. <i>Medicinal Research Reviews</i> , 2005, 25, 21-48.	5.0	176
172	N-Methyl-D-Aspartate Receptor in Human Prostate Cancer. <i>Journal of Membrane Biology</i> , 2005, 205, 125-128.	1.0	60
173	Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. <i>Psychopharmacology</i> , 2005, 180, 177-190.	1.5	119
174	Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. <i>Psychopharmacology</i> , 2005, 179, 85-98.	1.5	66
175	Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin. <i>Neurotoxicity Research</i> , 2005, 8, 167-186.	1.3	32
176	Treatment of vascular dementia: Evidence from epidemiologic studies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 219-225.	0.4	0
177	Glutamate Metabolizing Enzymes in Prefrontal Cortex of Alzheimer's Disease Patients. <i>Neurochemical Research</i> , 2005, 30, 1443-1451.	1.6	68
178	Glutamate Receptors: 7.2 NMDA Receptors. , 2005, , 389-428.		0
179	Glutamatergic compounds: a perspective. , 2005, , 205-216.		5
180	NMDA Antagonists and Neuropathic Pain - Multiple Drug Targets and Multiple Uses. <i>Current Pharmaceutical Design</i> , 2005, 11, 2977-2994.	0.9	127
181	The Molecular Basis of Memantine Action in Alzheimers Disease and Other Neurologic Disorders: Low-affinity, Uncompetitive Antagonism. <i>Current Alzheimer Research</i> , 2005, 2, 155-165.	0.7	228
182	Therapeutic Agents for Alzheimers Disease. <i>Current Medicinal Chemistry - Central Nervous System Agents</i> , 2005, 5, 259-269.	0.6	23
183	Improving human haptic performance in normal and impaired human populations through unattended activation-based learning. <i>ACM Transactions on Applied Perception</i> , 2005, 2, 71-88.	1.2	59
184	Excitatory Amino Acid Neurotransmission. , 2005, , 249-303.		28
185	Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block. <i>Journal of Neuroscience</i> , 2005, 25, 3312-3322.	1.7	205
186	Effects of the N-Methyl-d-aspartate Receptor Antagonist Perzinfotel [EAA-090; [2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic Acid] on Chemically Induced Thermal Hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1379-1386.	1.3	16

#	ARTICLE	IF	CITATIONS
187	Modulation of N-Methyl-d-aspartate Receptors by Donepezil in Rat Cortical Neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 125-135.	1.3	26
190	Emerging therapies for neuropathic pain. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 95-108.	1.0	33
191	Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. <i>European Neuropsychopharmacology</i> , 2005, 15, 219-225.	0.3	75
192	Glutamate Receptor Pharmacology: Lessons Learned from the Last Decade of Stroke Trials. , 2005, , 27-45.		3
193	Effects of memantine and donepezil on amyloid β^2 -induced memory impairment in a delayed-matching to position task in rats. <i>Behavioural Brain Research</i> , 2005, 162, 191-199.	1.2	71
194	Developing an exposureâ€“doseâ€“response model for the acute neurotoxicity of organic solvents: overview and progress on in vitro models and dosimetry. <i>Environmental Toxicology and Pharmacology</i> , 2005, 19, 607-614.	2.0	41
195	Peripherally acting NMDA receptor/glycine site receptor antagonists inhibit morphine tolerance. <i>Neuropharmacology</i> , 2005, 48, 360-371.	2.0	22
196	Dementia of Alzheimerâ€™s disease and other neurodegenerative disordersâ€”memantine, a new hope. <i>Pharmacological Research</i> , 2005, 51, 1-17.	3.1	268
199	Novel Dimeric Acetylcholinesterase Inhibitor Bis(7)-tacrine, but Not Donepezil, Prevents Glutamate-induced Neuronal Apoptosis by Blocking N-Methyl-d-aspartate Receptors. <i>Journal of Biological Chemistry</i> , 2005, 280, 18179-18188.	1.6	94
200	GABA and Glutamate Receptor Ligands and Their Therapeutic Potential in CNS Disorders. , 2005, , 797-907.		3
204	Synthesis and Pharmacology of Galantamine. <i>Chemical Reviews</i> , 2006, 106, 116-133.	23.0	240
205	Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model. <i>European Neuropsychopharmacology</i> , 2006, 16, 59-69.	0.3	68
206	Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. <i>European Neuropsychopharmacology</i> , 2006, 16, 297-310.	0.3	77
207	Tumor Necrosis Factor- β Induces Neurotoxicity via Glutamate Release from Hemichannels of Activated Microglia in an Autocrine Manner. <i>Journal of Biological Chemistry</i> , 2006, 281, 21362-21368.	1.6	648
208	Memantine. <i>Drugs</i> , 2006, 66, 1515-1534.	4.9	198
209	Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer's Disease. <i>Clinical Drug Investigation</i> , 2006, 26, 303-314.	1.1	10
210	Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 704-715.	0.6	260
211	Memantine for dementia. <i>The Cochrane Library</i> , 2006, , CD003154.	1.5	608

#	ARTICLE	IF	CITATIONS
212	Nitrous Oxide and Xenon Prevent Amphetamine-Induced Carrier-Mediated Dopamine Release in a Memantine-Like Fashion and Protect Against Behavioral Sensitization. <i>Biological Psychiatry</i> , 2006, 60, 49-57.	0.7	36
213	Differential pharmacological modulation of the spontaneous stimulus-independent activity in the rat spinal cord following peripheral nerve injury. <i>Experimental Neurology</i> , 2006, 198, 72-80.	2.0	64
214	Interruption of functional recovery by the NMDA glutamate antagonist MK801 after compression of the sensorimotor cortex: Implications for treatment of tumors or other mass-related brain injuries. <i>Experimental Neurology</i> , 2006, 200, 262-266.	2.0	8
215	Evidence for the involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. <i>Behavioural Brain Research</i> , 2006, 168, 318-322.	1.2	71
216	Mechanism of action of memantine. <i>Current Opinion in Pharmacology</i> , 2006, 6, 61-67.	1.7	390
217	Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice. <i>Neuroscience Letters</i> , 2006, 395, 93-97.	1.0	49
218	Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. <i>Neuroscience Letters</i> , 2006, 394, 196-201.	1.0	34
219	Insights from molecular investigations of traditional Chinese herbal stroke medicines: Implications for neuroprotective epilepsy therapy. <i>Epilepsy and Behavior</i> , 2006, 8, 350-362.	0.9	73
220	Functional in vitro characterization of CR 3394: A novel voltage dependent N-methyl-d-aspartate (NMDA) receptor antagonist. <i>Neuropharmacology</i> , 2006, 50, 277-285.	2.0	13
221	Molecular Pathogenesis of Huntington's Disease: The Role of Excitotoxicity. , 2006, , 251-260.		1
222	Effects of Eugenol on the Central Nervous System: Its Possible Application to Treatment of Alzheimers Disease, Depression, and Parkinsons Disease. <i>Current Bioactive Compounds</i> , 2006, 2, 57-66.	0.2	32
224	Applications of Multi-Electrode Array System in Drug Discovery Using Acute and Cultured Hippocampal Slices. , 2006, , 355-376.		1
225	Memantine in the treatment of Alzheimer's disease. <i>Aging Health</i> , 2006, 2, 891-904.	0.3	1
226	Intra-ventral pallidal glutamate antagonists block expression of morphine-induced place preference.. <i>Behavioral Neuroscience</i> , 2006, 120, 1103-1114.	0.6	33
227	Drug Treatment: Memantine. , 2006, , 123-130.		0
228	Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. <i>Behavioural Pharmacology</i> , 2006, 17, 411-424.	0.8	118
229	Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 17S-26S.	1.0	53
230	Alzheimer Disease and Its Management. <i>American Journal of Therapeutics</i> , 2006, 13, 516-526.	0.5	38

#	ARTICLE	IF	CITATIONS
231	Efficacy and Safety of Memantine in Moderate-to-Severe Alzheimer Disease: The Evidence to Date. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 23-29.	0.6	82
232	Neuroprotective properties of memantine in different <i>in vitro</i> and <i>in vivo</i> models of excitotoxicity. <i>European Journal of Neuroscience</i> , 2006, 23, 2611-2622.	1.2	154
233	The chemical biology of clinically tolerated NMDA receptor antagonists. <i>Journal of Neurochemistry</i> , 2006, 97, 1611-1626.	2.1	409
234	Multifunctional drugs with different CNS targets for neuropsychiatric disorders. <i>Journal of Neurochemistry</i> , 2006, 99, 1033-1048.	2.1	87
235	Trialkylglycines: A New Family of Compounds with <i>in Vivo</i> Neuroprotective Activity. <i>CNS Neuroscience & Therapeutics</i> , 2003, 9, 263-274.	4.0	4
236	The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease. <i>CNS Neuroscience & Therapeutics</i> , 2003, 9, 275-308.	4.0	328
237	Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 160-170.	21.5	765
238	Novel pharmacological targets for the treatment of Parkinson's disease. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 845-854.	21.5	262
239	Memantine Reduces Hematoma Expansion in Experimental Intracerebral Hemorrhage, Resulting in Functional Improvement. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 536-544.	2.4	88
240	Reinstatement of Morphine-Conditioned Reward is Blocked by Memantine. <i>Neuropsychopharmacology</i> , 2006, 31, 160-170.	2.8	65
241	Pharmacokinetic study of memantine in healthy and renally impaired subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 134-143.	2.3	89
242	Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice. <i>Psychopharmacology</i> , 2006, 187, 424-434.	1.5	25
243	New targets for pharmacological intervention in the glutamatergic synapse. <i>European Journal of Pharmacology</i> , 2006, 545, 2-10.	1.7	136
244	Memantine attenuates staurosporine-induced activation of caspase-3 and LDH release in mouse primary neuronal cultures. <i>Brain Research</i> , 2006, 1069, 145-153.	1.1	33
245	Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. <i>Brain Research</i> , 2006, 1088, 141-147.	1.1	29
246	Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. <i>Brain Research</i> , 2006, 1118, 199-207.	1.1	53
247	Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 298-306.	1.3	116
248	Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, 110, 135-370.		483

#	ARTICLE	IF	CITATIONS
249	Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opinion on Investigational Drugs, 2006, 15, 873-886.	1.9	61
250	Glutamate Receptors in Neuroinflammatory Demyelinating Disease. Mediators of Inflammation, 2006, 2006, 1-12.	1.4	69
251	The Effect of Drugs for Alzheimer Disease Assessed by Means of Neuroradiological Techniques. Current Medicinal Chemistry, 2006, 13, 3417-3424.	1.2	16
252	N-Methyl-D-Aspartate Receptor (NMDA) Antagonists as Potential Pain Therapeutics. Current Topics in Medicinal Chemistry, 2006, 6, 749-770.	1.0	37
253	Low Doses of Memantine Disrupt Memory in Adult Rats. Journal of Neuroscience, 2006, 26, 3923-3932.	1.7	119
254	Enhancement of Antidepressant-Like Effects but Not Brain-Derived Neurotrophic Factor mRNA Expression by the Novel N-Methyl-d-aspartate Receptor Antagonist Neramexane in Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1128-1136.	1.3	27
255	Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, 2006, 67, 57-63.	1.5	201
256	A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease. Archives of Neurology, 2006, 63, 49.	4.9	164
257	Coadministration of Memantine with Acetylcholinesterase Inhibitors. , 2006, , 35-46.		1
258	Pharmacology of Acetylcholinesterase Inhibitors and N-methyl-D-aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. Journal of Clinical Pharmacology, 2006, 46, 8S-16S.	1.0	69
259	Oxidative Stress in Anticholinesterase-Induced Excitotoxicity. , 2006, , 511-532.		16
260	Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APP ^{swe}) Transgenic Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 30-36.	1.3	57
261	Disease-modifying therapies for Alzheimer disease. Neurology, 2007, 69, 1622-1634.	1.5	261
262	Animal Behavior Case of the Month. Journal of the American Veterinary Medical Association, 2007, 231, 536-539.	0.2	22
263	Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties. Current Alzheimer Research, 2007, 4, 522-536.	0.7	28
264	Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation. Current Drug Targets, 2007, 8, 621-632.	1.0	180
265	Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2007, 8, 203-214.	0.9	49
266	Preclinical Investigation of the Functional Effects of Memantine and Memantine Combined with Galantamine or Donepezil. Neuropsychopharmacology, 2007, 32, 1284-1294.	2.8	35

#	ARTICLE	IF	CITATIONS
267	Advances in hemorrhagic stroke therapy: conventional and novel approaches. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 389-406.	1.0	45
268	Domain-Specific Improvement of Cognition on Memantine in Patients with Alzheimer's Disease Treated with Rivastigmine. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 301-306.	0.7	34
269	Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 247-252.	0.7	45
270	Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study. <i>Journal of Alzheimer's Disease</i> , 2007, 11, 471-479.	1.2	80
271	Memantine Acts as a Cholinergic Stimulant in the Mouse Hippocampus. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 319-333.	1.2	64
272	Multifunctional neuroprotective "neurorescue" drugs for Parkinson's disease. <i>Future Neurology</i> , 2007, 2, 411-423.	0.9	3
273	Acute Pancreatitis and Diabetic Ketoacidosis in a Schizophrenic Patient Taking Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 397-400.	0.7	21
274	Treatment of Antipsychotic-Associated Hyperglycemia With Pioglitazone. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 403-404.	0.7	11
275	Exacerbation of Myoclonus by Memantine in a Patient With Alzheimer Disease. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 407-408.	0.7	14
276	Depressive Symptoms in Urticaria Patients Treated With First- or Second-Generation Histamine 1 Receptor Antagonists. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 404-406.	0.7	3
277	Severe Hypoglycemia Following Venlafaxine Intoxication. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 414-415.	0.7	17
278	Use of Alcohol During the Treatment of Alcohol Dependence With β -Hydroxybutyric Acid. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 418.	0.7	5
279	Association of Acute Symptoms and Compliance Attitude in Noncompliant Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 392-394.	0.7	15
280	Cervical Dystonia Due to Interaction of Valproic Acid and Quetiapine. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 396-397.	0.7	14
281	Discontinuation of Risperidone, Olanzapine, and Haloperidol in First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 400-401.	0.7	2
282	An Open-Label Trial of Discontinuing Benzodiazepines in Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 401-403.	0.7	6
283	Lithium Toxicity Presenting as Catatonia in an Adolescent Girl. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 410-412.	0.7	13
284	Disulfiram in Context. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 415-417.	0.7	7

#	ARTICLE	IF	CITATIONS
285	Rating Rater Improvement. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 418-420.	0.7	18
286	Why Do Clinical Trials Fail?. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 420-421.	0.7	6
287	Reversible Delayed Onset Olanzapine-Associated Leukopenia and Neutropenia in a Clozapine-Naive Patient on Concomitant Depot Antipsychotic. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 394-395.	0.7	5
288	Olanzapine-Induced Chylomicronemia Presenting as Acute Pancreatitis. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 395-396.	0.7	15
289	Treatment Adherence in Individuals With Rapid Cycling Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 412-414.	0.7	21
290	Memantine for Alcohol Dependence: An Open-label Pilot Study. <i>Addictive Disorders and Their Treatment</i> , 2007, 6, 77-83.	0.5	12
291	An Open-label, Flexible-Dose Study of Memantine in Major Depressive Disorder. <i>Clinical Neuropharmacology</i> , 2007, 30, 136-144.	0.2	100
292	Levetiracetam for Manic Behavior in Hospitalized Geriatric Patients With Dementia of the Alzheimer's Type. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 408-410.	0.7	19
293	Reply to Comments by Mr Martin and Dr Beresford. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 417-418.	0.7	1
294	Reply to Comments by Drs Rickels and Robinson. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 421.	0.7	1
295	Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine. <i>Neuropharmacology</i> , 2007, 53, 415-420.	2.0	22
296	Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. <i>Neuropharmacology</i> , 2007, 53, 699-723.	2.0	593
297	Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model. <i>Behavioural Brain Research</i> , 2007, 179, 76-89.	1.2	203
298	Effects of NMDA receptor antagonist memantine on mismatch negativity. <i>Brain Research Bulletin</i> , 2007, 72, 275-283.	1.4	71
299	Changes in function of NMDA receptor NR2B subunit in spinal cord of rats with neuropathy following chronic ethanol consumption. <i>Life Sciences</i> , 2007, 80, 852-859.	2.0	21
300	Cyclophane and acyclic cyclophane: Novel channel blockers of N-methyl-d-aspartate receptor. <i>Neurochemistry International</i> , 2007, 50, 443-449.	1.9	11
301	Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. <i>Neuroscience Letters</i> , 2007, 411, 238-242.	1.0	50
302	The after-effect of human theta burst stimulation is NMDA receptor dependent. <i>Clinical Neurophysiology</i> , 2007, 118, 1028-1032.	0.7	486

#	ARTICLE	IF	CITATIONS
303	Meta-analysis of six-month memantine trials in Alzheimer's disease. , 2007, 3, 7-17.		88
304	Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?. Parkinsonism and Related Disorders, 2007, 13, S281-S291.	1.1	39
306	An update on the pharmacology of galantamine. Expert Opinion on Investigational Drugs, 2007, 16, 1987-1998.	1.9	67
308	Drug treatments for tinnitus. Progress in Brain Research, 2007, 166, 249-262.	0.9	49
309	Die Parkinson-Krankheit. , 2007, , .		12
310	Excitotoxicity. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 553-569.	1.0	1
311	A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 135-141.	1.5	26
312	Psychosis Induced by the Interaction of Memantine and Amantadine: Lending Evidence to the Glutamatergic Theory of Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2007, 1, 273-276.	1.4	2
313	Memantine as an Example of a Fast, Voltage-Dependent, Open Channel N-Methyl-d-Aspartate Receptor Blocker. Methods in Molecular Biology, 2007, 403, 15-36.	0.4	36
314	The Use of Cognitive Enhancers in Behavioral Disturbances of Alzheimer's Disease. The Consultant Pharmacist, 2007, 22, 754-762.	0.4	16
316	Mechanism-Based Development of Memantine as a Therapeutic Agent in Treating Alzheimer's Disease and Other Neurologic Disorders: Low-Affinity, Uncompetitive Antagonism with Fast Off-Rate. , 0, , 439-464.		0
317	Evaluation of Neuroimmunophilin Ligands. , 0, , 203-229.		1
318	Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. International Journal of Geriatric Psychiatry, 2007, 22, 258-262.	1.3	43
319	Synthesis of novel highly functionalized biologically active polycyclic caged amides. Tetrahedron Letters, 2007, 48, 6204-6208.	0.7	20
320	Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor. Bioorganic and Medicinal Chemistry, 2007, 15, 1525-1532.	1.4	42
321	Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. European Journal of Pain, 2007, 11, 299-308.	1.4	115
322	Marked Prevention of Ischemic Brain Injury by Neu2000, an NMDA Antagonist and Antioxidant Derived from Aspirin and Sulfasalazine. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1142-1151.	2.4	47
323	Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain. British Journal of Clinical Pharmacology, 2007, 64, 75-82.	1.1	12

#	ARTICLE	IF	CITATIONS
324	A Pilot Double-Blind Treatment Trial of Memantine for Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 775-782.	1.4	103
325	Fragments, network biology and designing multiple ligands. <i>Drug Discovery Today</i> , 2007, 12, 156-160.	3.2	200
326	Memantine and recognition memory: Possible facilitation of its behavioral effects by the nitric oxide (NO) donor molsidomine. <i>European Journal of Pharmacology</i> , 2007, 571, 174-179.	1.7	19
327	The uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task. <i>European Journal of Pharmacology</i> , 2007, 575, 98-102.	1.7	35
328	Mechanisms of blockade of glutamate receptor ionic channels: Paradox of 9-aminoacridine. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2007, 1, 88-95.	0.3	1
329	Memantine as Adjunctive Therapy in Children Diagnosed With Autistic Spectrum Disorders: An Observation of Initial Clinical Response and Maintenance Tolerability. <i>Journal of Child Neurology</i> , 2007, 22, 574-579.	0.7	199
330	Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. <i>Journal of Psychopharmacology</i> , 2007, 21, 259-271.	2.0	90
331	A retrospective study of memantine in children and adolescents with pervasive developmental disorders. <i>Psychopharmacology</i> , 2007, 191, 141-147.	1.5	135
332	Mechanisms of the blockade of glutamate channel receptors: Significance for structural and physiological investigations. <i>Neuroscience and Behavioral Physiology</i> , 2007, 37, 277-284.	0.2	1
333	A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists – in vitro characterization. <i>Journal of Neural Transmission</i> , 2007, 114, 1529-1537.	1.4	11
334	Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. <i>Journal of Neurology</i> , 2007, 254, 351-358.	1.8	34
335	Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 376, 295-300.	1.4	26
336	NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. <i>Psychopharmacology</i> , 2008, 196, 497-509.	1.5	52
337	Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia. <i>Psychopharmacology</i> , 2008, 196, 649-660.	1.5	29
338	The fraction of activated N-methyl-d-Aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole. <i>Journal of Neural Transmission</i> , 2008, 115, 1119-1126.	1.4	12
339	Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from <i>Xenopus</i> oocytes. <i>Journal of Neural Transmission</i> , 2008, 115, 1367-1373.	1.4	6
340	Distribution of an NMDA receptor:GFP fusion protein in sensory neurons is altered by a C-terminal construct. <i>Journal of Neurochemistry</i> , 2008, 77, 23-33.	2.1	1
341	Memantine agonist action at dopamine D2 ^{High} receptors. <i>Synapse</i> , 2008, 62, 149-153.	0.6	110

#	ARTICLE	IF	CITATIONS
342	Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown as by micromagnetic resonance imaging. <i>Journal of Neuroscience Research</i> , 2008, 86, 2784-2791.	1.3	114
343	Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter. <i>Glia</i> , 2008, 56, 233-240.	2.5	76
344	Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 537-545.	1.3	194
345	Fluorescent polycyclic ligands for nitric oxide synthase (NOS) inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8952-8958.	1.4	17
346	Effect of memantine on CBF and CMRO ₂ in patients with early Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2008, 117, 317-323.	1.0	18
347	Mg ²⁺ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in <i>Xenopus laevis</i> oocytes. <i>Journal of Physiology</i> , 2008, 586, 211-225.	1.3	39
348	Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. <i>Brain Research</i> , 2008, 1196, 113-120.	1.1	49
350	Memantine does not show intracellular block of the NMDA receptor channel. <i>European Journal of Pharmacology</i> , 2008, 587, 99-103.	1.7	16
351	Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration. <i>European Journal of Pharmacology</i> , 2008, 587, 135-140.	1.7	29
352	NMDA receptors in clinical neurology: excitatory times ahead. <i>Lancet Neurology</i> , The, 2008, 7, 742-755.	4.9	363
353	Clinically Tolerated Strategies for NMDA Receptor Antagonism. , 2008, , 327-361.		0
354	Memantine for the Treatment of Alzheimer's Disease. <i>Drug Safety</i> , 2008, 31, 577-585.	1.4	76
355	Non-Associative Learning in Larval Zebrafish. <i>Neuropsychopharmacology</i> , 2008, 33, 1206-1215.	2.8	197
356	The attenuating effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells. <i>Neurochemistry International</i> , 2008, 52, 864-877.	1.9	66
357	Memantine increases brain production of kynurenic acid via protein kinase A-dependent mechanism. <i>Neuroscience Letters</i> , 2008, 435, 169-173.	1.0	13
358	Memantine prevents MDMA-induced neurotoxicity. <i>NeuroToxicology</i> , 2008, 29, 179-183.	1.4	38
359	Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. <i>Neurobiology of Aging</i> , 2008, 29, 153-167.	1.5	51
360	mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. <i>Neurobiology of Aging</i> , 2008, 29, 1040-1051.	1.5	121

#	ARTICLE	IF	CITATIONS
361	Cognition-enhancing and anxiolytic effects of memantine. <i>Neuropharmacology</i> , 2008, 54, 1079-1085.	2.0	50
362	Inhibition of NMDA-gated ion channels by bis(7)-tacrine: Whole-cell and single-channel studies. <i>Neuropharmacology</i> , 2008, 54, 1086-1094.	2.0	18
363	Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. <i>Neuropharmacology</i> , 2008, 54, 1254-1263.	2.0	49
364	Driving GDNF expression: The green and the red traffic lights. <i>Progress in Neurobiology</i> , 2008, 86, 186-215.	2.8	91
365	Blockade of microglial glutamate release protects against ischemic brain injury. <i>Experimental Neurology</i> , 2008, 214, 144-146.	2.0	86
366	Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. <i>European Neuropsychopharmacology</i> , 2008, 18, 117-121.	0.3	53
367	Disease-modifying therapies in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2008, 4, 65-79.	0.4	132
368	Memantine Protects Against Secondary Neuronal Degeneration in Lateral Geniculate Nucleus and Superior Colliculus after Retinal Damage in Mice. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 192-202.	1.9	15
369	Pharmacodynamics of Memantine: An Update. <i>Current Neuropharmacology</i> , 2008, 6, 55-78.	1.4	141
370	Pharmacological treatment in moderate-to-severe Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2575-2582.	0.9	21
371	NMDA Receptor Blockade with Memantine Attenuates White Matter Injury in a Rat Model of Periventricular Leukomalacia. <i>Journal of Neuroscience</i> , 2008, 28, 6670-6678.	1.7	153
372	Memantine Potentiates Agonist-Induced Ca^{2+} Responses in HEK 293 Cells. <i>Cellular Physiology and Biochemistry</i> , 2008, 22, 205-214.	1.1	14
373	Effects of memantine and MK-801 on ischemia in an experimental model of acute subdural hematoma. <i>Neurological Research</i> , 2008, 30, 497-503.	0.6	9
374	Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. <i>FASEB Journal</i> , 2008, 22, 1275-1286.	0.2	99
375	Glutamatergic Approaches to the Treatment of Cognitive and Behavioural Symptoms of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2008, 5, 241-243.	0.8	47
376	Ca ²⁺ Inhibits the Association of Memantine with N-Methyl-D-aspartate (NMDA) Receptor-Gated Ion Channels. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1813-1815.	0.6	2
377	Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 193-199.	1.2	50
378	Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2008, 118, 1532-1543.	3.9	193

#	ARTICLE	IF	CITATIONS
379	Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. <i>Behavioural Pharmacology</i> , 2008, 19, 724-734.	0.8	29
380	The NMDA Receptor and Alcohol Addiction. <i>Frontiers in Neuroscience</i> , 2008, , 59-77.	0.0	6
381	Serotonin 5-HT ₆ Receptor Antagonists for the Treatment of Alzheimers Disease. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1035-1048.	1.0	57
382	Influence of NMDA and non-NMDA antagonists on acute and inflammatory pain in the trigeminal territory: a placebo control study. <i>Arquivos De Neuro-Psiquiatria</i> , 2008, 66, 837-843.	0.3	9
383	A Review of Glutamate Receptors I: Current Understanding of Their Biology. <i>Journal of Toxicologic Pathology</i> , 2008, 21, 25-51.	0.3	39
384	Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 553.	1.0	14
385	NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review. <i>Journal of Receptor, Ligand and Channel Research</i> , 2009, Volume 2, 59-73.	0.7	4
386	Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine. <i>Current Molecular Pharmacology</i> , 2009, 2, 77-82.	0.7	47
387	Excitotoxicity, Oxidative Stress, and Neuronal Injury. , 2009, , 633-651.		4
388	Chronic Nicotine Selectively Enhances $\alpha 4\beta 2^*$ Nicotinic Acetylcholine Receptors in the Nigrostriatal Dopamine Pathway. <i>Journal of Neuroscience</i> , 2009, 29, 12428-12439.	1.7	95
389	Pharmacological Interventions in Primary Care: Hopes and Illusions. <i>Frontiers of Neurology and Neuroscience</i> , 2009, 24, 54-65.	3.0	5
390	Effects of Topiramate and Other Anti-Glutamatergic Drugs on the Acute Intoxicating Actions of Ethanol in Mice: Modulation by Genetic Strain and Stress. <i>Neuropsychopharmacology</i> , 2009, 34, 1454-1466.	2.8	20
391	Current approaches with the glutamatergic system as targets in the treatment of neuropathic pain. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 925-943.	1.5	13
392	Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine. <i>Brain</i> , 2009, 132, 2464-2477.	3.7	66
393	Differential Involvement of Glutamatergic Mechanisms in the Cognitive and Subjective Effects of Smoking. <i>Neuropsychopharmacology</i> , 2009, 34, 257-265.	2.8	40
394	Use of memantine in treatment of canine compulsive disorders. <i>Journal of Veterinary Behavior: Clinical Applications and Research</i> , 2009, 4, 118-126.	0.5	28
395	Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. <i>Brain Research</i> , 2009, 1254, 128-137.	1.1	39
396	Memantine treatment reduces the expression of the K ⁺ /Cl ⁻ cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABA _A receptor activation in mice. <i>Brain Research</i> , 2009, 1265, 75-79.	1.1	20

#	ARTICLE	IF	CITATIONS
397	Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury. <i>Brain Research</i> , 2009, 1282, 173-182.	1.1	47
398	Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 532-538.	1.3	65
399	Cell death: protein misfolding and neurodegenerative diseases. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 455-468.	2.2	167
400	An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 900-912.	2.2	43
401	Perspectives in designing anti aggregation agents as Alzheimer disease drugs. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3866-3873.	2.6	10
402	N-Methyl-d-aspartate Receptor Antagonists Have Variable Affect in 3-Nitropropionic Acid Toxicity. <i>Neurochemical Research</i> , 2009, 34, 490-498.	1.6	11
403	Protective Effect of Memantine Against Doxorubicin Toxicity in Primary Neuronal Cell Cultures: Influence a Development Stage. <i>Neurotoxicity Research</i> , 2009, 15, 24-37.	1.3	25
404	Transcranial magnetic stimulation, synaptic plasticity and network oscillations. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2009, 6, 7.	2.4	124
405	Polycyclic Compounds: Ideal Drug Scaffolds for the Design of Multiple Mechanism Drugs?. <i>Neurotherapeutics</i> , 2009, 6, 175-186.	2.1	55
406	NMDA receptor antagonist memantine promotes cell proliferation and production of mature granule neurons in the adult hippocampus. <i>Neuroscience Research</i> , 2009, 63, 259-266.	1.0	75
407	Determination of Memantine in Human Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. <i>Chromatographia</i> , 2009, 70, 783-788.	0.7	14
408	Memantine. <i>CNS Drugs</i> , 2009, 23, 881-897.	2.7	74
409	Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2009, 378, 507-512.	1.0	39
410	The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. <i>Neuropharmacology</i> , 2009, 56, 6-21.	2.0	138
411	Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. <i>Neuropharmacology</i> , 2009, 56, 866-875.	2.0	63
412	Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. <i>Neuropharmacology</i> , 2009, 57, 121-126.	2.0	76
413	Postsynaptic density-membrane associated guanylate kinase proteins (PSD-MAGUKs) and their role in CNS disorders. <i>Neuroscience</i> , 2009, 158, 324-333.	1.1	64
414	Different effects of two N-methyl-d-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. <i>Epilepsy and Behavior</i> , 2009, 14, 32-39.	0.9	58

#	ARTICLE	IF	CITATIONS
415	Evidence for glutamatergic neurotransmission in cognitive control in an auditory attention task. <i>Neuroscience Letters</i> , 2009, 454, 171-175.	1.0	16
417	Current investigational drugs for major depression. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 767-788.	1.9	88
418	<i>Skeletal Muscle.</i> , 2009, , 509-531.		6
419	Anti-apoptotic effect of memantine against staurosporine- and low-potassium-induced cell death in cerebellar granule cells: a development-dependent effect. <i>Pharmacological Reports</i> , 2009, 61, 827-837.	1.5	10
420	Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimer's Disease. <i>CNS Drugs</i> , 2009, 23, 293-307.	2.7	68
421	The effects of the glutamate antagonist memantine on brain activation to an auditory perception task. <i>Human Brain Mapping</i> , 2009, 30, 3616-3624.	1.9	20
422	Influence of Memantine on Brain Monoaminergic Neurotransmission Parameters in Mice: Neurochemical and Behavioral Study. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 850-855.	0.6	31
423	Increase of desensitization as an additional mode of action for classical NMDA receptor channel blockers. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2010, 4, 302-308.	0.3	0
424	A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. <i>Psychopharmacology</i> , 2010, 212, 227-242.	1.5	55
425	New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 46-57.	1.4	19
426	Redox Reactions Induced by Nitrosative Stress Mediate Protein Misfolding and Mitochondrial Dysfunction in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2010, 41, 55-72.	1.9	130
427	Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study. <i>Annals of Nuclear Medicine</i> , 2010, 24, 363-369.	1.2	22
428	Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson's Disease Complicated by Dementia. <i>Neuroscience and Behavioral Physiology</i> , 2010, 40, 149-155.	0.2	47
429	Effects of Memantine on Convulsive Reactions and the Organization of Sleep in Krushinski's "Molodkina Rats with an Inherited Predisposition to Audiogenic Convulsions. <i>Neuroscience and Behavioral Physiology</i> , 2010, 40, 913-919.	0.2	5
430	NMR elucidation of novel SQ109 derivatives. <i>Structural Chemistry</i> , 2010, 21, 1203-1209.	1.0	2
431	Regulation of Kv2.1 phosphorylation in an animal model of anoxia. <i>Neurobiology of Disease</i> , 2010, 38, 85-91.	2.1	12
432	NMDA-receptor antagonist and morphine decrease CRPS-pain and cerebral pain representation. <i>Pain</i> , 2010, 151, 69-76.	2.0	91
433	Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application. <i>Electrophoresis</i> , 2010, 31, 1903-1911.	1.3	39

#	ARTICLE	IF	CITATIONS
435	Memantine lowers amyloid β peptide levels in neuronal cultures and in APP/PS1 transgenic mice. <i>Journal of Neuroscience Research</i> , 2010, 88, 143-154.	1.3	112
436	Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. <i>European Journal of Neurology</i> , 2010, 17, 405-412.	1.7	50
437	Inverse relationship between seizure expression and extrasynaptic NMDAR function following chronic NMDAR inhibition. <i>Epilepsia</i> , 2010, 51, 102-105.	2.6	6
438	Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents. <i>Experimental Neurobiology</i> , 2010, 19, 1-14.	0.7	38
439	Repetitive Electric Stimulation Elicits Enduring Improvement of Sensorimotor Performance in Seniors. <i>Neural Plasticity</i> , 2010, 2010, 1-11.	1.0	39
440	Network Excitability Dysfunction in Alzheimer's Disease: Insights from In Vitro and In Vivo Models. <i>Reviews in the Neurosciences</i> , 2010, 21, 153-71.	1.4	35
441	A 1H-MR Spectroscopy Study of Changes in Glutamate and Glutamine (Glx) Concentrations in Frontal Spectra after Administration of Memantine. <i>Cerebral Cortex</i> , 2010, 20, 798-803.	1.6	37
442	New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid β Peptide. <i>Analytical Chemistry</i> , 2010, 82, 10083-10089.	3.2	50
443	Therapy for dyskinesias in Parkinson's disease patients. <i>Future Neurology</i> , 2010, 5, 277-299.	0.9	1
444	Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Disorders?. <i>Rambam Maimonides Medical Journal</i> , 2010, 1, e0011.	0.4	6
445	S 24795 Limits β -Amyloid β 7 Nicotinic Receptor Interaction and Reduces Alzheimer's Disease-Like Pathologies. <i>Biological Psychiatry</i> , 2010, 67, 522-530.	0.7	51
446	N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression. , 2010, , 1-20.		0
447	Glutamate and Neurodegenerative Disease. <i>Topics in Medicinal Chemistry</i> , 2010, , 91-147.	0.4	4
448	Differential pharmacological responses of catatonia-like signs in frontotemporal dementia. <i>Neurocase</i> , 2010, 16, 436-450.	0.2	14
449	Glutamate Receptor Ion Channels: Structure, Regulation, and Function. <i>Pharmacological Reviews</i> , 2010, 62, 405-496.	7.1	2,973
450	REVIEW: An Approach for Neuroprotective Therapies of Secondary Brain Damage after Excitotoxic Retinal Injury in Mice. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, e169-79.	1.9	3
452	Spotlight on Memantine in Moderate to Severe Alzheimer's Disease. <i>Drugs and Aging</i> , 2010, 27, 177-179.	1.3	12
453	Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1765-1771.	0.9	27

#	ARTICLE	IF	CITATIONS
454	Multifunctional Roles of Activins in the Brain. <i>Vitamins and Hormones</i> , 2011, 85, 185-206.	0.7	20
455	Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. <i>Behavioural Brain Research</i> , 2011, 221, 610-622.	1.2	116
456	Management of moderate to severe Alzheimer's disease: Focus on memantine. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2011, 50, 415-423.	0.5	21
457	Quantification of the Mg ²⁺ -induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. <i>Neuropharmacology</i> , 2011, 60, 388-396.	2.0	25
458	Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. <i>Neuroscience</i> , 2011, 182, 88-97.	1.1	76
459	Memantine reduces mania-like symptoms in animal models. <i>Psychiatry Research</i> , 2011, 188, 366-371.	1.7	31
460	Sensing change: The emerging role of calcium sensors in neuronal disease. <i>Seminars in Cell and Developmental Biology</i> , 2011, 22, 530-535.	2.3	21
461	Current and Emerging Therapies for the Management of Bipolar Disorders. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S4441.	0.7	9
462	Memantine and Catatonia. <i>Journal of Psychiatric Practice</i> , 2011, 17, 292-299.	0.3	31
463	Targeting the Kynurenine Pathway-Related Alterations in Alzheimer's Disease: A Future Therapeutic Strategy. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 199-209.	1.2	26
464	Effects of Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist, on Genomic Stability. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 413-417.	1.2	17
465	Syntheses and Pharmacological Evaluations of Novel N-Substituted Bicycloheptaneamines at <i>N</i> -Methyl-L-Aspartate Receptors. <i>Chemical Biology and Drug Design</i> , 2011, 78, 25-32.	1.5	7
466	On the antioxidant properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress. <i>Neurotoxicology and Teratology</i> , 2011, 33, 538-547.	1.2	251
467	Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid- β peptide and surface reorganization. <i>International Journal of Pharmaceutics</i> , 2011, 416, 453-460.	2.6	25
468	Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-d-aspartate receptor and voltage gated calcium channel ligands. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5010-5020.	2.6	26
469	How were new medicines discovered?. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 507-519.	21.5	1,516
470	A role for glutamate in subjective response to smoking and its action on inhibitory control. <i>Psychopharmacology</i> , 2011, 216, 29-42.	1.5	13
471	Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3935-3944.	1.4	27

#	ARTICLE	IF	CITATIONS
472	A new HPLC method with fluorescence detection for the determination of memantine in human plasma. <i>Journal of Separation Science</i> , 2011, 34, 2645-2649.	1.3	16
473	The effect of co-administration of the NMDA blocker with agonist and antagonist of CB1-receptor on penicillin-induced epileptiform activity in rats. <i>Epilepsy Research</i> , 2011, 93, 128-137.	0.8	27
474	Brain Glutamate Levels Are Decreased in Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2011, 26, 450-456.	0.9	98
475	Activation of Brain Histaminergic Neurotransmission: A Mechanism for Cognitive Effects of Memantine in Alzheimer's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 479-487.	1.3	24
476	Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder. <i>International Journal of Adolescent Medicine and Health</i> , 2011, 23, 167-73.	0.6	21
477	An Open-Label, Multicenter Observational Study for Patients with Alzheimer's Disease Treated with Memantine in the Clinical Practice. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 10-19.	0.6	2
478	Acute postoperative pain management in the older patient. <i>Aging Health</i> , 2011, 7, 813-828.	0.3	15
479	Neuroprotection against Traumatic Brain Injury by a Peptide Derived from the Collapsin Response Mediator Protein 2 (CRMP2). <i>Journal of Biological Chemistry</i> , 2011, 286, 37778-37792.	1.6	78
480	N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer's Disease, Vascular Dementia and Parkinson's Disease. <i>Current Alzheimer Research</i> , 2012, 9, 746-758.	0.7	277
481	Basic Pharmacology of NMDA Receptors. <i>Current Pharmaceutical Design</i> , 2012, 18, 1558-1567.	0.9	57
482	False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine. <i>Brain</i> , 2012, 135, 2103-2114.	3.7	49
483	Novel NMDA receptor modulators: an update. <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 1337-1352.	2.4	69
484	Influence of memantine on nociceptive responses of the trigeminocervical complex after formalin injection. <i>Cephalalgia</i> , 2012, 32, 308-316.	1.8	11
486	Alzheimer's disease, β -amyloid, glutamate, NMDA receptors and memantine – searching for the connections. <i>British Journal of Pharmacology</i> , 2012, 167, 324-352.	2.7	396
487	Memantine Improves Safety of Thrombolysis for Stroke. <i>Stroke</i> , 2012, 43, 2774-2781.	1.0	32
488	Memantine potentiates hippocampal theta oscillations at a therapeutic dose in anesthetized mice: A mechanistic link to its cognitive-enhancing properties. <i>Neuropharmacology</i> , 2012, 62, 2208-2218.	2.0	24
489	Targeted treatments in autism and fragile X syndrome. <i>Research in Autism Spectrum Disorders</i> , 2012, 6, 1311-1320.	0.8	41
490	Targeting the Glutamatergic System to Treat Major Depressive Disorder. <i>Drugs</i> , 2012, 72, 1313-1333.	4.9	181

#	ARTICLE	IF	CITATIONS
491	Memantine combined with environmental enrichment improves spatial memory and alleviates Alzheimer's disease-like pathology in senescence-accelerated prone-8 (SAMP8) mice. <i>Journal of Biomedical Research</i> , 2012, 26, 439.	0.7	16
492	Stabilizers of Neuronal and Mitochondrial Calcium Cycling as a Strategy for Developing a Medicine for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2012, 3, 873-883.	1.7	33
493	Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid β 40. <i>European Journal of Pharmacology</i> , 2012, 692, 38-45.	1.7	23
494	Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. <i>Neuropharmacology</i> , 2012, 63, 769-775.	2.0	35
495	Determination of memantine in human plasma by GC using negative ion chemical ionization MS detection after derivatization with a new reagent. <i>Mikrochimica Acta</i> , 2012, 178, 309-314.	2.5	13
496	The Role of Memantine in the Treatment of Psychiatric Disorders Other Than the Dementias. <i>CNS Drugs</i> , 2012, 26, 663-690.	2.7	257
497	Quantitative determination of memantine in human plasma by GC using negative ion chemical ionization MS detection after derivatization with a new reagent, o-(pentafluorobenzoyloxycarbonyl)-2,3,4,5-tetrafluorobenzoyl chloride. <i>Mikrochimica Acta</i> , 2012, 179, 249-255.	2.5	1
498	Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit. <i>Aging Clinical and Experimental Research</i> , 2012, 24, 193-196.	1.4	9
499	Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. <i>Metabolic Brain Disease</i> , 2012, 27, 175-182.	1.4	74
500	Low-Dose Memantine Attenuated Morphine Addictive Behavior Through its Anti-Inflammation and Neurotrophic Effects in Rats. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 444-453.	2.1	64
501	Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. <i>European Journal of Pharmacology</i> , 2012, 682, 1-11.	1.7	60
502	Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 942-948.	1.4	17
503	Electrochemical synthesis of methyl-3,5,7-trifluoroadamantane-1-carboxylate under recycling use of ionic liquid media. <i>Journal of Fluorine Chemistry</i> , 2012, 140, 28-30.	0.9	11
504	Neuroprotective effect of noncompetitive NMDA receptor antagonists IEM-1957 and memantine in experimental focal cerebral ischemia. <i>Doklady Biological Sciences</i> , 2012, 443, 78-80.	0.2	2
505	Kynurenes and intestinal neurotransmission: the role of N-methyl-d-aspartate receptors. <i>Journal of Neural Transmission</i> , 2012, 119, 211-223.	1.4	52
506	Recent advances in the multitargeted ligands approach for the treatment of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2013, 33, 139-189.	5.0	394
507	The influence of glutamatergic antagonism on motor variability, and comparison to findings in schizophrenia patients. <i>Acta Neuropsychiatrica</i> , 2013, 25, 105-112.	1.0	6
508	Common influences of non-competitive NMDA receptor antagonists on the consolidation and reconsolidation of cocaine-cue memory. <i>Psychopharmacology</i> , 2013, 226, 707-719.	1.5	37

#	ARTICLE	IF	CITATIONS
509	The uncompetitive NMDA receptor antagonists ketamine and memantine preferentially increase the choice for a small, immediate reward in low-impulsive rats. <i>Psychopharmacology</i> , 2013, 226, 127-138.	1.5	42
510	Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine. <i>Psychopharmacology</i> , 2013, 225, 187-199.	1.5	5
511	Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. <i>European Journal of Pharmacology</i> , 2013, 703, 53-61.	1.7	51
512	Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2013, 24, 358-369.	1.3	246
513	Memantine Protects Rats Treated with Intrathecal Methotrexate from Developing Spatial Memory Deficits. <i>Clinical Cancer Research</i> , 2013, 19, 4446-4454.	3.2	38
514	Glutamate in Parkinson's disease: Role of ant glutamatergic drugs. <i>Basal Ganglia</i> , 2013, 3, 147-157.	0.3	20
515	Orally bioavailable small molecule drug protects memory in Alzheimer's disease models. <i>Neurobiology of Aging</i> , 2013, 34, 1116-1125.	1.5	16
516	Selective introduction of fluorine atoms to the tert-carbons of functionalized adamantanes by BrF ₃ . <i>Journal of Fluorine Chemistry</i> , 2013, 145, 128-131.	0.9	7
517	Preparation and testing of homocubyl amines as therapeutic NMDA receptor antagonists. <i>Medicinal Chemistry Research</i> , 2013, 22, 360-366.	1.1	25
518	mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. <i>Behavioural Brain Research</i> , 2013, 247, 9-16.	1.2	51
519	Cognitive impairments and cancer chemotherapy: Translational research at a crossroads. <i>Life Sciences</i> , 2013, 93, 589-595.	2.0	16
520	7-Methoxytacrine-Adamantylamine Heterodimers as Cholinesterase Inhibitors in Alzheimer's Disease Treatment – Synthesis, Biological Evaluation and Molecular Modeling Studies. <i>Molecules</i> , 2013, 18, 2397-2418.	1.7	63
521	The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives. <i>Chemical Reviews</i> , 2013, 113, 3516-3604.	23.0	517
522	Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-to-severe Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013, 9, 326-331.	0.4	90
523	Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 115-129.	2.5	51
525	Memantine, a promising drug for the prevention of neuropathic pain in rat. <i>European Journal of Pharmacology</i> , 2013, 721, 382-390.	1.7	29
526	Treatment of the Ppt1 Mouse Model of Infantile Neuronal Ceroid Lipofuscinosis With the N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine. <i>Journal of Child Neurology</i> , 2013, 28, 1159-1168.	0.7	14
527	Memantine may affect pseudobulbar affect in patients with Alzheimer's disease. <i>Acta Neuropsychiatrica</i> , 2013, 25, 361-366.	1.0	7

#	ARTICLE	IF	CITATIONS
528	Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 336-342.	0.7	48
529	Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats. <i>Journal of Psychopharmacology</i> , 2013, 27, 152-161.	2.0	22
530	Synaptic and extrasynaptic plasticity in glutamatergic circuits involving dentate granule cells following chronic <i>N</i> -methyl-D-aspartate receptor inhibition. <i>Journal of Neurophysiology</i> , 2013, 109, 1535-1547.	0.9	13
531	Development of NMDAR Antagonists with Reduced Neurotoxic Side Effects: a Study on GK11. <i>PLoS ONE</i> , 2013, 8, e81004.	1.1	10
532	Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases. <i>Current Medicinal Chemistry</i> , 2013, 20, 1662-1672.	1.2	83
533	Protein Profiles Associated With Context Fear Conditioning and Their Modulation by Memantine. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 919-937.	2.5	15
534	Clinical observation of acupuncture-moxibustion for Alzheimer's disease. <i>Journal of Acupuncture and Tuina Science</i> , 2014, 12, 354-357.	0.1	2
535	The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development. <i>Current Medicinal Chemistry</i> , 2014, 21, 3551-3575.	1.2	132
536	Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 671-680.	1.0	11
537	Effect of the A β Aggregation Modulator MRZ-99030 on Retinal Damage in an Animal Model of Glaucoma. <i>Neurotoxicity Research</i> , 2014, 26, 440-446.	1.3	24
538	<i>N</i> -Methyl-D-Aspartate Receptor Blockade Is Neuroprotective in Experimental Autoimmune Optic Neuritis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 507-518.	0.9	35
539	The Effects of Add-On Low-Dose Memantine on Cytokine Levels in Bipolar II Depression. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 337-343.	0.7	39
540	Effects of Ionotropic Glutamate Receptor Blockers on Pentylenetetrazole-Induced Seizures in Krushinski's Molodkina Rats. <i>Neuroscience and Behavioral Physiology</i> , 2014, 44, 945-950.	0.2	3
541	Glutamate and Neurodegeneration in the Retina. , 2014, , 1273-1285.		0
542	Pharmacotherapy of bipolar disorder: current status and emerging options. <i>Clinical Practice (London, England)</i> , 2014, 11, 39-48.	0.1	2
543	Effects of Ionotropic Glutamate Channel Blockers on Audiogenic Seizure Reactions in Krushinski's Molodkina Rats. <i>Neuroscience and Behavioral Physiology</i> , 2014, 44, 79-86.	0.2	2
544	Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. <i>Neuroscience</i> , 2014, 265, 245-252.	1.1	33
545	From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. <i>Drug Testing and Analysis</i> , 2014, 6, 614-632.	1.6	199

#	ARTICLE	IF	CITATIONS
546	Time-dependent enhancement of hippocampus-dependent memory after treatment with memantine: Implications for enhanced hippocampal adult neurogenesis. <i>Hippocampus</i> , 2014, 24, 784-793.	0.9	44
547	Effects of memantine treatment on language abilities and functional communication: A review of data. <i>Aphasiology</i> , 2014, 28, 236-257.	1.4	12
548	The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. <i>Brain Research</i> , 2014, 1551, 25-44.	1.1	30
549	Differential Effects of Synaptic and Extrasynaptic NMDA Receptors on Al^{2+} -Induced Nitric Oxide Production in Cerebrocortical Neurons. <i>Journal of Neuroscience</i> , 2014, 34, 5023-5028.	1.7	51
550	Synaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in an in vitro model of limbic epileptogenesis. <i>Neuropharmacology</i> , 2014, 77, 379-386.	2.0	15
551	Adamantane amine derivatives as dual acting NMDA receptor and voltage-gated calcium channel inhibitors for neuroprotection. <i>MedChemComm</i> , 2014, 5, 1678-1684.	3.5	13
552	Retrieval-induced NMDA receptor-dependent Arc expression in two models of cocaine-cue memory. <i>Neurobiology of Learning and Memory</i> , 2014, 116, 79-89.	1.0	23
553	Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients. <i>Contemporary Clinical Trials</i> , 2014, 38, 314-320.	0.8	9
554	Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 299-314.	2.5	17
555	Potential pharmacological strategies for the improved treatment of organophosphate-induced neurotoxicity. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014, 92, 893-911.	0.7	34
556	Prevention of post-mastectomy neuropathic pain with memantine: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 331.	0.7	12
557	Effects of Ionotropic Glutamate Receptor Channel Blockers on the Organization of Sleep in Rats. <i>Neuroscience and Behavioral Physiology</i> , 2014, 44, 365-370.	0.2	3
558	Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8649-8654.	3.3	186
559	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged <i>Octodon degus</i> . <i>Neuropharmacology</i> , 2014, 85, 206-214.	2.0	21
560	Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test. <i>Acta Neuropsychiatrica</i> , 2015, 27, 228-234.	1.0	13
561	Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial. <i>Scientific Reports</i> , 2015, 5, 10140.	1.6	16
562	Evoking plasticity through sensory stimulation: Implications for learning and rehabilitation. <i>E-Neuroforum</i> , 2015, 21, .	0.2	1
563	<i>Skeletal Muscle</i> . , 2015, , 577-597.		1

#	ARTICLE	IF	CITATIONS
564	Protein Dynamics Associated with Failed and Rescued Learning in the Ts65Dn Mouse Model of Down Syndrome. <i>PLoS ONE</i> , 2015, 10, e0119491.	1.1	31
565	Combination effect of memantine and mesenchymal stem cells on the recovery of brain damage in a rat model of brain ischemia. <i>Animal Cells and Systems</i> , 2015, 19, 110-118.	0.8	1
566	Molecular construction of multitarget neuroprotectors 1. Synthesis and biological activity of conjugates of substituted indoles and bis(dimethylamino)phenothiazine. <i>Russian Chemical Bulletin</i> , 2015, 64, 1354-1361.	0.4	11
567	Synthesis and biological activity of N-substituted tetrahydro- β -carbolins bearing bis(dimethylamino)phenothiazine moiety. <i>Russian Chemical Bulletin</i> , 2015, 64, 718-722.	0.4	15
568	Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an <i>in vitro</i> human blood-brain barrier model. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 182-187.	1.1	38
569	Influence of Ionotropic Glutamate Receptor Channel Blockers on the Effects of Sleep Deprivation in Rats. <i>Neuroscience and Behavioral Physiology</i> , 2015, 45, 295-301.	0.2	0
570	Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. <i>Nature Neuroscience</i> , 2015, 18, 435-443.	7.1	168
571	Effect of Memantine on Cough Reflex Sensitivity: Translational Studies in Guinea Pigs and Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 448-454.	1.3	15
572	Long-term oral administration of the NMDA receptor antagonist memantine extends life span in spinocerebellar ataxia type 1 knock-in mice. <i>Neuroscience Letters</i> , 2015, 592, 37-41.	1.0	12
573	Excitotoxicity, Oxidative Stress, and Neuronal Injury. , 2015, , 709-724.		2
574	Procognitive Compounds Promote Neurite Outgrowth. <i>Pharmacology</i> , 2015, 96, 131-136.	0.9	13
575	Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1001, 131-139.	1.2	32
576	The Ability of NMDA-Type Glutamate Receptor Blockers to Prevent the Development of Pentylentetrazole Kindling and Morphological Changes to Pyramidal Neurons in the Mouse Hippocampus. <i>Neuroscience and Behavioral Physiology</i> , 2015, 45, 528-535.	0.2	5
577	Assessing the translational feasibility of pharmacological drug memory reconsolidation blockade with memantine in quitting smokers. <i>Psychopharmacology</i> , 2015, 232, 3363-3374.	1.5	31
578	Effects of memantine on hippocampal long-term potentiation, gamma activity, and sensorimotor gating in freely moving rats. <i>Neurobiology of Aging</i> , 2015, 36, 2544-2554.	1.5	14
579	Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. <i>Neurological Sciences</i> , 2015, 36, 1633-1641.	0.9	27
580	1,2-Naphthoquinone-4-sulfonic acid sodium salt as a reagent for spectrophotometric determination of rimantadine and memantine. <i>Journal of Analytical Chemistry</i> , 2015, 70, 320-327.	0.4	7
581	A Combination Therapy of 17 β -Estradiol and Memantine Is More Neuroprotective Than Monotherapies in an Organotypic Brain Slice Culture Model of Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2015, 32, 1361-1368.	1.7	16

#	ARTICLE	IF	CITATIONS
582	Evoking plasticity through sensory stimulation: Implications for learning and rehabilitation. <i>E-Neuroforum</i> , 2015, 6, 11-20.	0.2	6
583	NMDA and GABA receptors as potential targets in cough hypersensitivity syndrome. <i>Current Opinion in Pharmacology</i> , 2015, 22, 29-36.	1.7	34
584	Altered nociception in mice with genetically induced hypoglutamatergic tone. <i>Neuroscience</i> , 2015, 293, 80-91.	1.1	8
585	NMDAR-Mediated Hippocampal Neuronal Death is Exacerbated by Activities of ASIC1a. <i>Neurotoxicity Research</i> , 2015, 28, 122-137.	1.3	18
586	Suppression of excitotoxicity and foreign body response by memantine in chronic cannula implantation into the rat brain. <i>Brain Research Bulletin</i> , 2015, 117, 54-68.	1.4	8
587	Validation and application of a simple reverse phase HPLC method for in vitro dissolution studies of memantine hydrochloride tablet. <i>Journal of Pharmaceutical Investigation</i> , 2015, 45, 415-421.	2.7	6
588	Glutamate Receptors within the Mesolimbic Dopamine System Mediate Alcohol Relapse Behavior. <i>Journal of Neuroscience</i> , 2015, 35, 15523-15538.	1.7	44
589	Aging Mechanisms. , 2015, , .		4
590	N ^α -methyl-DL-aspartate receptor channel blockers prevent pentylenetetrazole-induced convulsions and morphological changes in rat brain neurons. <i>Journal of Neuroscience Research</i> , 2015, 93, 454-465.	1.3	50
591	Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. <i>Addiction Biology</i> , 2015, 20, 890-901.	1.4	25
592	Memantine Alleviates Brain Injury and Neurobehavioral Deficits after Experimental Subarachnoid Hemorrhage. <i>Molecular Neurobiology</i> , 2015, 51, 1038-1052.	1.9	31
593	Immunomodulation by memantine in therapy of Alzheimer's disease is mediated through inhibition of Kv1.3 channels and T cell responsiveness. <i>Oncotarget</i> , 2016, 7, 53797-53807.	0.8	16
594	Synaptic Conductances during Interictal Discharges in Pyramidal Neurons of Rat Entorhinal Cortex. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 233.	1.8	25
595	Synthesis of adamantane functional derivatives basing on N-[(adamantan-1-yl)alkyl]acetamides. <i>Russian Journal of Organic Chemistry</i> , 2016, 52, 1558-1564.	0.3	7
596	Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats. <i>Brain Research</i> , 2016, 1642, 389-396.	1.1	12
597	Modeling and simulation of organophosphate-induced neurotoxicity: Prediction and validation by experimental studies. <i>NeuroToxicology</i> , 2016, 54, 140-152.	1.4	22
598	Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment. <i>Behavioural Brain Research</i> , 2016, 311, 1-14.	1.2	34
600	Memantine, an NMDA receptor antagonist, improves working memory deficits in DCK1 ² knockout mice. <i>Neuroscience Letters</i> , 2016, 630, 228-232.	1.0	8

#	ARTICLE	IF	CITATIONS
601	Novel Targets for Drug Treatment in Psychiatry. , 2016, , 601-654.		0
602	The effects of memantine on recovery, cognitive functions, and pain after propofol anesthesia. Brazilian Journal of Anesthesiology (Elsevier), 2016, 66, 485-491.	0.2	7
603	Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy, 2016, 17, 1669-1682.	0.9	14
604	Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking. Neuropsychopharmacology, 2016, 41, 2062-2071.	2.8	70
605	Bangle (<i>Zingiber purpureum</i>) Improves Spatial Learning, Reduces Deficits in Memory, and Promotes Neurogenesis in the Dentate Gyrus of Senescence-Accelerated Mouse P8. Journal of Medicinal Food, 2016, 19, 435-441.	0.8	13
606	Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice. Acta Pharmacologica Sinica, 2016, 37, 166-176.	2.8	15
607	The Calpain Inhibitor A-705253 Attenuates Alcohol-Seeking and Relapse with Low Side-Effect Profile. Neuropsychopharmacology, 2016, 41, 979-988.	2.8	10
608	The potential utility of some legal highs in CNS disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 267-274.	2.5	12
609	Memantine (Generic and Namenda XR). , 2016, , 174-180.		0
610	Microwave assisted synthesis of novel hybrid tacrine-sulfonamide derivatives and investigation of their antioxidant and anticholinesterase activities. Bioorganic Chemistry, 2017, 70, 245-255.	2.0	28
611	Therapeutics of Neurotransmitters in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 57, 1049-1069.	1.2	169
612	Therapeutic targeting of the pathological triad of extrasynaptic NMDA receptor signaling in neurodegenerations. Journal of Experimental Medicine, 2017, 214, 569-578.	4.2	119
613	Memantine reduces the production of amyloid- β peptides through modulation of amyloid precursor protein trafficking. European Journal of Pharmacology, 2017, 798, 16-25.	1.7	31
614	Memantine-induced chorea and dystonia. Practical Neurology, 2017, 17, 133-134.	0.5	9
615	Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson's disease in rats. Pathophysiology, 2017, 24, 71-79.	1.0	35
616	Convenient Synthesis of Memantine Hydrochloride. Organic Preparations and Procedures International, 2017, 49, 155-162.	0.6	18
617	Regulation of Human Brain Microvascular Endothelial Cell Adhesion and Barrier Functions by Memantine. Journal of Molecular Neuroscience, 2017, 62, 123-129.	1.1	35
618	Supramolecular Hydrogels Fabricated from Supramonomers: A Novel Wound Dressing Material. ACS Applied Materials & Interfaces, 2017, 9, 11368-11372.	4.0	135

#	ARTICLE	IF	CITATIONS
619	Synthesis of novel pyrazolyl derivatives of 1,3-diazaadamantane. <i>Chemistry of Heterocyclic Compounds</i> , 2017, 53, 192-195.	0.6	0
620	Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease. <i>Medical Hypotheses</i> , 2017, 99, 57-62.	0.8	33
621	Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. <i>Nature Reviews Neurology</i> , 2017, 13, 52-64.	4.9	338
622	Memantine inhibits β -amyloid aggregation and disassembles preformed β -amyloid aggregates. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 158-163.	1.0	22
623	Classics in Chemical Neuroscience: Memantine. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1823-1829.	1.7	55
624	Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 80, 555-572.	2.9	31
625	Pharmacotherapy for Vascular Cognitive Impairment. <i>CNS Drugs</i> , 2017, 31, 759-776.	2.7	110
626	A New Synthetic Approach to β -Symmetric Octacyclic Cage Diol via Claisen Rearrangement and Ring-Closing Metathesis as Key Steps. <i>ChemistrySelect</i> , 2017, 2, 6877-6881.	0.7	9
627	GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. <i>Neuropharmacology</i> , 2017, 123, 322-331.	2.0	50
628	A support vector machine approach to identification of proteins relevant to learning in a mouse model of Down Syndrome. , 2017, , .		5
629	Incorporation of dihydroartemisinin into memantine through a propiate spacer to make hybrid with enhanced effects to protect PC12 cells from corticosterone-caused impairments. <i>Chemical Research in Chinese Universities</i> , 2017, 33, 611-622.	1.3	3
630	Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 44-50.	0.7	32
631	Memantine Reduced Cell Death, Astrogliosis, and Functional Deficits in an <i>in vitro</i> Model of Repetitive Mild Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2017, 34, 934-942.	1.7	22
632	NMDA receptor antagonist prevents cell death in the hippocampal dentate gyrus induced by hyponatremia accompanying adrenal insufficiency in rats. <i>Experimental Neurology</i> , 2017, 287, 65-74.	2.0	8
633	Ionotropic glutamate receptors: Still exciting after all these years. <i>Neuropharmacology</i> , 2017, 112, 1-3.	2.0	2
634	Do specific NMDA receptor subunits act as gateways for addictive behaviors?. <i>Genes, Brain and Behavior</i> , 2017, 16, 118-138.	1.1	59
635	Enhanced LTP in aged rats: Detrimental or compensatory?. <i>Neuropharmacology</i> , 2017, 114, 12-19.	2.0	25
636	Antinociceptive Activity of <i>Borreria verticillata</i> : In vivo and In silico Studies. <i>Frontiers in Pharmacology</i> , 2017, 8, 283.	1.6	12

#	ARTICLE	IF	CITATIONS
637	Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. <i>PLoS ONE</i> , 2017, 12, e0180319.	1.1	22
638	Glutamate and Its Receptors as Therapeutic Targets for Migraine. <i>Neurotherapeutics</i> , 2018, 15, 361-370.	2.1	93
639	Non-competitive antagonists of NMDA and AMPA receptors decrease seizure-induced c-fos protein expression in the cerebellum and protect against seizure symptoms in adult rats. <i>Acta Histochemica</i> , 2018, 120, 236-241.	0.9	11
640	Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1044-1050.	1.4	8
641	Memantine treatment of juvenile rats with kaolin-induced hydrocephalus. <i>Brain Research</i> , 2018, 1689, 54-62.	1.1	2
642	Amyloids of multiple species: are they helpful in survival?. <i>Biological Reviews</i> , 2018, 93, 1363-1386.	4.7	11
643	Psychotomimetic-like behavioral effects of memantine in the mouse. <i>Biomedicine and Pharmacotherapy</i> , 2018, 100, 116-123.	2.5	9
644	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-1 α and angiogenesis inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1547-1559.	1.4	14
645	Excessive Activation of NMDA Receptors Induced Neurodevelopmental Brain Damage and Cognitive Deficits in Rats Exposed to Intrauterine Hypoxia. <i>Neurochemical Research</i> , 2018, 43, 566-580.	1.6	13
646	The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action. <i>European Journal of Pharmacology</i> , 2018, 827, 103-111.	1.7	35
647	Discovery and development of NA-1 for the treatment of acute ischemic stroke. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 661-668.	2.8	69
648	Memantine improves outcomes after repetitive traumatic brain injury. <i>Behavioural Brain Research</i> , 2018, 340, 195-204.	1.2	43
649	A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice. <i>Clinical Journal of Pain</i> , 2018, 34, 450-467.	0.8	98
650	Memantine for the treatment of general neuropathic pain: a narrative review. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 4-13.	1.0	28
651	Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia. <i>Molecular Neuropsychiatry</i> , 2018, 4, 134-148.	3.0	21
652	Commentary: GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 315.	1.4	2
653	Ketamine influences the locus coeruleus norepinephrine network, with a dependency on norepinephrine transporter genotype â€” a placebo controlled fMRI study. <i>NeuroImage: Clinical</i> , 2018, 20, 715-723.	1.4	29
654	Differential Effects of Extended Exercise and Memantine Treatment on Adult Neurogenesis in Male and Female Rats. <i>Neuroscience</i> , 2018, 390, 241-255.	1.1	17

#	ARTICLE	IF	CITATIONS
655	Memantine has no effect on KATP channels in pancreatic \hat{I}^2 cells. BMC Research Notes, 2018, 11, 614.	0.6	5
656	How Visual Body Perception Influences Somatosensory Plasticity. Neural Plasticity, 2018, 2018, 1-12.	1.0	6
657	Sublimation thermodynamics aspects of adamantane and memantine derivatives of sulfonamide molecular crystals. Physical Chemistry Chemical Physics, 2018, 20, 19784-19791.	1.3	10
658	The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta ($A\beta^2$) species on long-term potentiation (LTP). Neuropharmacology, 2018, 140, 184-192.	2.0	22
659	Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models. Molecular Neuropsychiatry, 2019, 5, 178-189.	3.0	14
660	A Snapshot on the Current Status of Alzheimer's Disease, Treatment Perspectives, &in-Vitro& and &in-Vivo& Research Studies and Future Opportunities. Chemical and Pharmaceutical Bulletin, 2019, 67, 1030-1041.	0.6	8
661	Acute and chronic effects of single dose memantine after controlled cortical impact injury in adult rats. Restorative Neurology and Neuroscience, 2019, 37, 245-263.	0.4	3
662	Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease. Journal of Pharmacy and Pharmacology, 2019, 71, 1695-1705.	1.2	24
663	Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer's Disease in Mice. Bioconjugate Chemistry, 2019, 30, 2573-2583.	1.8	63
664	The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2019, 13, e0007226.	1.3	6
665	The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer's Disease Patients and Its Consequence to Oxidative Stress Biomarkers. Frontiers in Pharmacology, 2019, 10, 943.	1.6	13
666	Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry and Clinical Neurosciences, 2019, 73, 613-627.	1.0	239
667	N-Methyl-D-Aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats. European Journal of Neuroscience, 2019, 50, 2847-2859.	1.2	15
668	Nanoparticles and neurotoxicity: Dual response of glutamatergic receptors. Progress in Brain Research, 2019, 245, 281-303.	0.9	24
669	Extracellular mild acidosis decreases the Ca ²⁺ permeability of the human NMDA receptors. Cell Calcium, 2019, 80, 63-70.	1.1	8
670	Potential Pharmacokinetic Drug-Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-D-Aspartate Receptor Antagonist. Molecules, 2019, 24, 1430.	1.7	5
671	Synthesis and Pharmacological Properties of 1-(6-Aminohexylamino)-1-Phenylcyclohexyl Dihydrochloride (IEM-2062) as Compared with Memantine. Pharmaceutical Chemistry Journal, 2019, 53, 29-34.	0.3	4
672	Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis. Drugs and Aging, 2019, 36, 435-452.	1.3	36

#	ARTICLE	IF	CITATIONS
673	Cognitive Enhancer Effects of Low Memantine Doses Are Facilitated by an Alpha7 Nicotinic Acetylcholine Receptor Agonist in Scopolamine-Induced Amnesia in Rats. <i>Frontiers in Pharmacology</i> , 2019, 10, 73.	1.6	19
674	Label-free real-time imaging of extracellular Ca ²⁺ uptake in the hippocampal slice using Ca-PVC membrane based on charge-transfer-type potentiometric sensor arrays. , 2019, , .		1
675	Memantine for dementia. <i>The Cochrane Library</i> , 2019, 3, CD003154.	1.5	166
676	Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence. <i>Toxicology Reports</i> , 2019, 6, 1164-1175.	1.6	48
677	Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism. <i>Frontiers in Neurology</i> , 2019, 10, 1258.	1.1	6
678	Synthesis and Pharmacological Properties of Adamantane-Containing Bis-Cationic Compounds. <i>Pharmaceutical Chemistry Journal</i> , 2019, 52, 830-834.	0.3	3
679	Interplay between Gating and Block of Ligand-Gated Ion Channels. <i>Brain Sciences</i> , 2020, 10, 928.	1.1	7
680	Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?. <i>Biomolecules</i> , 2020, 10, 1134.	1.8	13
681	The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia. <i>Medicine (United States)</i> , 2020, 99, e21242.	0.4	5
682	Evaluation of spinal cord protective threshold of serum memantine, an NMDA receptor antagonist, in a rabbit model of paraplegia. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 36, 598-607.	0.2	0
683	Memantine Improves Depressive-like Behaviors via Kir6.1 Channel Inhibition in Olfactory Bulbectomized Mice. <i>Neuroscience</i> , 2020, 442, 264-273.	1.1	9
684	Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT ₆ and D ₃ receptors as hubs. <i>Neuropharmacology</i> , 2020, 177, 108099.	2.0	22
685	Encoding, Consolidation, and Renormalization in Depression: Synaptic Homeostasis, Plasticity, and Sleep Integrate Rapid Antidepressant Effects. <i>Pharmacological Reviews</i> , 2020, 72, 439-465.	7.1	28
686	Microglial Sirtuin 2 Shapes Long-Term Potentiation in Hippocampal Slices. <i>Frontiers in Neuroscience</i> , 2020, 14, 614.	1.4	7
687	Effect of memantine on expression of Bace1-as and Bace1 genes in STZ-induced Alzheimeric rats. <i>Molecular Biology Reports</i> , 2020, 47, 5737-5745.	1.0	5
688	Skeletal muscle. , 2020, , 589-611.		1
689	Excitotoxicity, oxidative stress, and neuronal injury. , 2020, , 795-810.		2
690	Multifunctional memantine nitrate significantly protects against glutamate-induced excitotoxicity via inhibiting calcium influx and attenuating PI3K/Akt/GSK3beta pathway. <i>Chemico-Biological Interactions</i> , 2020, 325, 109020.	1.7	21

#	ARTICLE	IF	CITATIONS
691	Interrelation of thermodynamic sublimation characteristics with crystal structure: adamantane and memantine derivatives of sulfonamide molecular crystals. <i>CrystEngComm</i> , 2020, 22, 2573-2584.	1.3	3
692	The NMDA Receptor Channel Blockers Memantine and IEM-1921 Decrease the Duration of Status Epilepticus in Wistar and Krushinskiï Molodkina Rats in a Lithium-Pilocarpine Model. <i>Neuroscience and Behavioral Physiology</i> , 2020, 50, 374-383.	0.2	2
693	Randomized trial to assess safety/feasibility of memantine administration during residential treatment for alcohol use disorder: a pilot study. <i>Journal of Addictive Diseases</i> , 2020, 38, 91-99.	0.8	2
694	Novel Therapeutic Approach for Excitatory/Inhibitory Imbalance in Neurodevelopmental and Neurodegenerative Diseases. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 701-721.	4.2	24
695	Add-on memantine may improve cognitive functions and attenuate inflammation in middle- to old-aged bipolar II disorder patients. <i>Journal of Affective Disorders</i> , 2021, 279, 229-238.	2.0	3
696	Memantine protects bloodâ€ brain barrier integrity and attenuates neurological deficits through inhibiting nitric oxide synthase ser1412 phosphorylation in intracerebral hemorrhage rats: involvement of peroxynitrite-related matrix metalloproteinase-9/NLRP3 inflammasome activation. <i>NeuroReport</i> , 2021, 32, 228-237.	0.6	10
697	Influence of Hemantane on Changes in Ca ²⁺ and Na ⁺ Caused by Activation of NMDA Channels in Cultured Rat Brain Neurons. <i>Neurochemical Journal</i> , 2021, 15, 8-17.	0.2	1
699	Memantine in neurological disorders â€ schizophrenia and depression. <i>Journal of Molecular Medicine</i> , 2021, 99, 327-334.	1.7	27
700	Contributions of animal models of cognitive disorders to neuropsychopharmacology. <i>Therapie</i> , 2021, 76, 87-99.	0.6	2
701	Effect of Memantine on Pentylentetrazol-induced Seizures and EEG Profile in Animal Model of Cortical Malformation. <i>Neuroscience</i> , 2021, 457, 114-124.	1.1	4
702	Anticonvulsant Action of GluN2A-Preferring Antagonist PEAQX in Developing Rats. <i>Pharmaceutics</i> , 2021, 13, 415.	2.0	5
703	Comparison of the Pharmacological Activity and Safety of 1-Adamantylguanidine and 3,5-Dimethyl-1-Adamantylguanidine to those of Memantine. <i>Pharmaceutical Chemistry Journal</i> , 2021, 54, 1198-1204.	0.3	1
704	N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo: Evidence from an NMDA-induced seizure model in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 203, 173154.	1.3	4
705	The multiple faces of ketamine in anaesthesia and analgesia. <i>Drugs in Context</i> , 2021, 10, 1-14.	1.0	12
706	Current Neuropharmacological Interventions in Autism: Potential Drug Targets from Pre-clinical and Clinical Findings. <i>Current Psychopharmacology</i> , 2021, 10, 98-114.	0.1	0
707	Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule. <i>World Journal of Psychiatry</i> , 2021, 11, 297-315.	1.3	20
708	Promising tacrine/huperzine Aâ€based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget. <i>Journal of Neurochemistry</i> , 2021, 158, 1381-1393.	2.1	13
709	Anxiogenic and anxiolytic effects of memantine injected into the ventral hippocampus in male stressed mice. <i>Journal of Complementary and Integrative Medicine</i> , 2021, .	0.4	1

#	ARTICLE	IF	CITATIONS
710	Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. <i>British Journal of Pharmacology</i> , 2021, 178, 4588-4607.	2.7	27
711	A tribute to Chris Parsons. <i>Neuropharmacology</i> , 2021, 195, 108633.	2.0	2
712	Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?. <i>World Journal of Psychiatry</i> , 2021, 11, 568-580.	1.3	3
713	Memantine exerts neuroprotective effects by modulating $\hat{\iota}$ -synuclein transmission in a parkinsonian model. <i>Experimental Neurology</i> , 2021, 344, 113810.	2.0	8
714	Memantine and its benefits for cancer, cardiovascular and neurological disorders. <i>European Journal of Pharmacology</i> , 2021, 910, 174455.	1.7	9
715	Mechanistic insights into the efficacy of memantine in treating certain drug addictions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110409.	2.5	9
716	Improving Translational Research Outcomes for Opioid Use Disorder Treatments. <i>Current Addiction Reports</i> , 2021, 8, 109-121.	1.6	9
717	Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical stroke. <i>Neural Regeneration Research</i> , 2021, 16, 433.	1.6	27
718	<i>Huperzia serrata</i> and the Constitute of Huperzine A Attenuate MK-801-Induced Cognitive Dysfunction in Mice <i>via</i> PKC-Erk Pathway. <i>BPB Reports</i> , 2021, 4, 155-161.	0.1	1
719	Effects of Memantine in Patients with Traumatic Brain Injury: A Systematic Review. <i>Trauma Care</i> , 2021, 1, 1-14.	0.4	1
720	Understanding and Treating Alzheimer<sup>TM</sup>s Disease. , 2006, , 49-70.		1
721	Neuroinflammation and Excitotoxicity in Neurobiology of HIV-1 Infection and AIDS: Targets for Neuroprotection. , 2007, , 281-308.		2
722	Neuroprotectants Targeting NMDA Receptor Signaling. , 2014, , 1381-1402.		2
723	Glutamate Receptor Ligands. , 2007, , 217-249.		31
724	The N-methyl-D-aspartate antagonist memantine retards progression of Huntington<sup>TM</sup>s disease. <i>Journal of Neural Transmission Supplementum</i> , 2004, , 117-122.	0.5	79
725	Current drugs and future hopes in the treatment of Alzheimer<sup>TM</sup>s disease. <i>Journal of Neural Transmission Supplementum</i> , 2002, , 149-164.	0.5	8
726	Knowledge of Signal Transduction Provides an Approach to Attacking Memory Decline. , 2015, , 257-274.		2
727	$\hat{\iota}$ 7 Nicotinic ACh Receptors as a Ligand-Gated Source of Ca ²⁺ Ions: The Search for a Ca ²⁺ Optimum. <i>Advances in Experimental Medicine and Biology</i> , 2012, 740, 603-638.	0.8	54

#	ARTICLE	IF	CITATIONS
728	Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. <i>Neurotherapeutics</i> , 2004, 1, 101-110.	2.1	1
729	Uncompetitive Antagonists of the N-Methyl-D-aspartate (NMDA) Receptors Alter the mRNA Expression of Proteins Associated with the NMDA Receptor Complex. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2001, 88, 98-105.	0.0	22
730	Pharmacology of the vestibular system. <i>Current Opinion in Neurology</i> , 2000, 13, 31-37.	1.8	24
731	Measurement of Amino Acid Levels in the Vitreous Humor of Rats after Chronic Intraocular Pressure Elevation or Optic Nerve Transection. <i>Journal of Glaucoma</i> , 2002, 11, 396-405.	0.8	81
732	Caffeine withdrawal syndrome in social interaction test in mice: Effects of the NMDA receptor channel blockers, memantine and neramexane. <i>Behavioural Pharmacology</i> , 2004, 15, 207-214.	0.8	12
733	Memantinium chloride 0.1-hydrate. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2009, 65, o2191-o2191.	0.2	5
734	Pharmacology of NMDA Receptors. <i>Frontiers in Neuroscience</i> , 2008, , 257-281.	0.0	3
735	A Review of Glutamate Receptors II: Pathophysiology and Pathology. <i>Journal of Toxicologic Pathology</i> , 2008, 21, 133-173.	0.3	15
736	Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2008, 30, 43.	0.8	83
737	NMDA Receptor Antagonist Attenuates Bleomycin-Induced Acute Lung Injury. <i>PLoS ONE</i> , 2015, 10, e0125873.	1.1	37
738	Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment. <i>PLoS ONE</i> , 2015, 10, e0145441.	1.1	20
739	NMDA Receptor Antagonists Disinhibit Rat Posterior Cingulate and Retrosplenial Cortices: A Potential Mechanism of Neurotoxicity. <i>Journal of Neuroscience</i> , 2002, 22, 3070-3080.	1.7	108
740	Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. <i>Oncotarget</i> , 2016, 7, 55840-55862.	0.8	66
741	Comparing the Effect of Memantine and Placebo on Clinical Outcome of Intracranial Hemorrhage: A Randomized Double Blind Clinical Trial. <i>Caspian Journal of Neurological Sciences</i> , 2015, 1, 11-18.	0.1	7
742	Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 245-258.	1.0	35
743	NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy. <i>Current Pharmaceutical Design</i> , 2019, 25, 3506-3518.	0.9	76
744	Memantine and Kynurenic Acid: Current Neuropharmacological Aspects. <i>Current Neuropharmacology</i> , 2016, 14, 200-209.	1.4	38
745	Mygalin: A New Anticonvulsant Polyamine in Acute Seizure Model and Neuroethological Schedule. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2013, 13, 122-131.	0.5	7

#	ARTICLE	IF	CITATIONS
746	Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications. <i>International Journal of Transpersonal Studies</i> , 2014, 33, 84-140.	0.2	20
747	A Review on Current Strategies and Future Perspective in Respect to Alzheimer's Disease Treatment. <i>Current Research in Neuroscience</i> , 2015, 6, 1-15.	0.0	4
748	Medications used in dementia: a review of evidence. <i>Sri Lanka Journal of Psychiatry</i> , 2015, 6, 3.	0.1	1
749	Adding Memantine to Rivastigmine Therapy in Patients With Mild-to-Moderate Alzheimer's Disease. Primary Care Companion To the <i>Journal of Clinical Psychiatry</i> , 2006, 8, 258-63.	0.6	25
750	Nanotechnology Building Blocks for Intervention with Alzheimer's Disease Pathology: Implications in Disease Modifying Strategies. <i>Journal of Bioanalysis & Biomedicine</i> , 2014, 06, .	0.1	12
751	Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study. <i>Psychiatry Investigation</i> , 2012, 9, 166.	0.7	38
752	A 10-Week Memantine Treatment in Bipolar Depression: A Case Report. Focus on Depressive Symptomatology, Cognitive Parameters and Quality of Life. <i>Psychiatry Investigation</i> , 2013, 10, 421.	0.7	22
753	Can Amantadine Ameliorate Neurocognitive Functions After Subarachnoid Haemorrhage? A Preliminary Study. <i>Turkish Journal of Anaesthesiology and Reanimation</i> , 2018, 46, 100-107.	0.8	11
754	Glutamate and Neurodegeneration in the Retina. , 2022, , 1-14.		0
755	Are vestibular hair cells excited to death by aminoglycoside antibiotics?. <i>Journal of Vestibular Research: Equilibrium and Orientation</i> , 2000, 10, 1-5.	0.8	8
756	Pharmacology of NMDA receptors. <i>Pharmaceutical Science Series</i> , 2001, , 69-98.	0.0	0
757	Glutamate Transmission in the Pathogenesis of Parkinson's Disease. , 2004, , 229-242.		1
758	Anti-Excitotoxic Therapies in Neurologic Diseases: Current Evidences and New Perspectives. , 2004, , 339-354.		0
759	Dopaminergic and Glutamatergic Systems in Alzheimer's Disease. , 2005, , 569-581.		0
760	Use of psychotropics in special patient groups. , 2005, , 259-335.		1
761	Molecular Mechanism of Memantine in Treatment of Alzheimer's Disease and Other Neurologic Insults. , 2005, , 351-372.		0
762	Multifunctional Neuroprotective Drugs for the Treatment of Alzheimer's Disease. , 2007, , 274-295.		0
763	Molecular Neurology of HIV-1 Infection and AIDS. , 2007, , 553-571.		0

#	ARTICLE	IF	CITATIONS
765	Excitatory Amino Acids, S-Nitrosylation, and Protein Misfolding in Neurodegenerative. Oxidative Stress and Disease, 2009, , .	0.3	0
766	Role of Ketamine in Managing Opioid-Induced Hyperalgesia. , 2009, , 124-133.		0
768	Memantine (Namenda). , 2011, , 184-192.		0
769	Synthesis and Antiviral Evaluation of Bisnoradamantane Sulfites and Related Compounds. Medicinal Chemistry, 2011, 7, 135-140.	0.7	0
770	Memantine Abolishes Anticholinergic Activity in Patient with Alzheimer's Disease at Moderate Stage. , 2012, 02, .		3
771	Patch Clamp Combined with Voltage/Concentration Clamp to Determine the Kinetics and Voltage Dependency of N-Methyl-d-aspartate (NMDA) Receptor Open Channel Blockers. Methods in Molecular Biology, 2014, 1183, 43-63.	0.4	1
772	BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF MEMANTINE HYDROCHLORIDE BY SPECTROFLUORIMETRIC METHOD USING OPA Î-MERCAPTOETHANOL AS DERIVATIZING AGENT. Indian Drugs, 2014, 51, 12-16.	0.1	0
773	Ifenprodil for trigeminal neuralgia with resistance to carbamazepine. Palliative Care Research, 2015, 10, 501-504.	0.0	0
774	Alzheimer's Disease Management: Current Therapy and Recent Drug Development. International Neuropsychiatric Disease Journal, 2016, 7, 1-19.	0.1	0
775	Phenomenon of Excitotoxicity as the Object of Pharmacologic Effect in Dementia. International Neurological Journal, 2016, .	0.2	0
779	Non-drug therapies for cognitive impairment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 68-77.	0.2	5
780	THE EFFECTIVENESS OF MEMANTINE ADMINISTRATON IN PATIENTS WITH NON-DEMENTIA COGNITIVE IMPAIRMENT. THE RESULTS OF A MULTICENTRE CLINICAL FOLLOW-UP STUDY. Russian Neurological Journal, 2019, , 37-44.	0.1	4
781	Use of akatinol memantine for the treatment of Korsakoff's syndrome: a clinical case. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2020, 12, 124-130.	0.2	0
782	Memantine and Alzheimer's disease. , 2020, , 511-527.		1
783	The Effect of Memantine Administration on Anxiety Maintenance in Stressed Male Wistar Rats. Iranian Journal of Psychiatry and Behavioral Sciences, 2020, 13, .	0.1	0
784	IEM-1925, a Glutamate Receptor Channel Blocker, Increases the Latent Period and Decreases the Duration of Status Epilepticus in Rats in a Lithium-Pilocarpine Model of Epilepsy. Neuroscience and Behavioral Physiology, 2021, 51, 976.	0.2	0
785	Stress-Induced Spatial Memory Deficit Reversed by Basolateral Amygdala NMDA Receptor Inhibition in Male Wistar Rats. Basic and Clinical Neuroscience, 2020, 11, 447-456.	0.3	0
786	An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury. Molecular Vision, 2011, 17, 1024-33.	1.1	11

#	ARTICLE	IF	CITATIONS
787	Memantine: a review of possible uses in child and adolescent psychiatry. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2013, 22, 166-71.	0.7	35
788	Interaction of Memantine with Homocysteine on the Apoptosis in the Rat Hippocampus cells. <i>International Journal of Molecular and Cellular Medicine</i> , 2012, 1, 145-52.	1.1	9
789	Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial. <i>Shanghai Archives of Psychiatry</i> , 2013, 25, 244-53.	0.7	1
790	Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study. <i>Journal of Research in Medical Sciences</i> , 2014, 19, 525-30.	0.4	20
793	Memantine: Features and application in the management of chronic pain. , 2022, , 121-130.		0
795	The Presence of the Temporal Horn Exacerbates the Vulnerability of Hippocampus During Head Impacts. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 754344.	2.0	10
796	Overview of Cannabis including Kampo Medicine and Therapy for Treatment of Dementia: A Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 713228.	1.6	2
797	The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer's Disease-like Pathology. <i>Journal of Clinical Medicine</i> , 2022, 11, 1858.	1.0	8
798	An exit beyond the pharmacophore model for 5-HT ₆ R agents - a new strategy to gain dual 5-HT ₆ /5-HT _{2A} action for triazine derivatives with procognitive potential. <i>Bioorganic Chemistry</i> , 2022, 121, 105695.	2.0	8
799	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114354.	2.6	10
802	Computational Modeling of Therapy with the NMDA Antagonist in Neurodegenerative Disease: Information Theory in the Mechanism of Action of Memantine. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4727.	1.2	5
804	Repeated spatial acquisition: effects of NMDA antagonists and morphine. <i>Experimental and Clinical Psychopharmacology</i> , 2003, 11, 79-90.	1.3	8
806	Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer's Disease, in Silico Trials. <i>Pharmaceuticals</i> , 2022, 15, 546.	1.7	8
808	Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review. <i>Frontiers in Psychiatry</i> , 2022, 13, .	1.3	12
809	Memantine in the Prevention of Radiation-Induced Brain Damage: A Narrative Review. <i>Cancers</i> , 2022, 14, 2736.	1.7	4
810	NMDA receptor antagonists reduce amyloid- β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	13
811	Altered Cortical Trigeminal Fields Excitability by Spreading Depolarization Revealed with <i>in Vivo</i> Functional Ultrasound Imaging Combined with Electrophysiology. <i>Journal of Neuroscience</i> , 2022, 42, 6295-6308.	1.7	3
812	Protein quality control of N-methyl-D-aspartate receptors. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	5

#	ARTICLE	IF	CITATIONS
813	Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 119, 110609.	2.5	8
814	Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study. <i>Neurology and Therapy</i> , 2022, 11, 1583-1594.	1.4	3
815	Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult. <i>Toxicology in Vitro</i> , 2022, 84, 105453.	1.1	3
816	Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, .	1.5	3
817	LEKI WIELOCELOWE – NOWY PARADYGMAT W PROJEKTOWANIU LEKÓW. , 2013, 11, 1-10.		0
818	Memantine for Treatment of Dementia. , 2022, , 2723-2731.		0
819	An Expeditious Spectrophotometric Estimation of Memantine Hydrochloride by Facile Derivatization Using N,N-Dimethyl Aniline. <i>Journal of Analytical Chemistry</i> , 2022, 77, 1433-1439.	0.4	0
820	Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15114.	1.8	17
821	A Review on Recent Development of Novel Heterocycles as Acetylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease. <i>Current Drug Targets</i> , 2023, 24, 225-246.	1.0	4
822	Amyloid β^{12} pathology in Alzheimer's disease: A nano delivery approach. <i>Vibrational Spectroscopy</i> , 2023, 126, 103510.	1.2	3
823	Glutamate and Neurodegeneration in the Retina. , 2022, , 1955-1968.		0
829	Memantine-Based Derivatives: Synthesis and Their Biological Evaluation. , 2023, , 185-209.		0